80 results on '"Aba, Mahamat"'
Search Results
2. Q Fever as a Cause of Community-Acquired Pneumonia in French Guiana
- Author
-
Loïc Epelboin, Aba Mahamat, Timothée Bonifay, Magalie Demar, Philippe Abboud, Gaëlle Walter, Anne-Sophie Drogoul, Alain Berlioz-Arthaud, Mathieu Nacher, Didier Raoult, Félix Djossou, Carole Eldin, Centre Hospitalier Andrée Rosemon [Cayenne, Guyane Française], Ecosystemes Amazoniens et Pathologie Tropicale (EPat), Institut National de la Santé et de la Recherche Médicale (INSERM)-Université de Guyane (UG), Centre hospitalier d'Ajaccio, Université des Antilles (Pôle Guadeloupe), Université des Antilles (UA), Institut Pasteur de la Guyane, Réseau International des Instituts Pasteur (RIIP), Centre d'Investigation Clinique Antilles-Guyane (CIC - Antilles Guyane), Université des Antilles et de la Guyane (UAG)-Institut National de la Santé et de la Recherche Médicale (INSERM)-CHU Pointe-à-Pitre/Abymes [Guadeloupe] -CHU de Fort de France-Centre Hospitalier Andrée Rosemon [Cayenne, Guyane Française], Institut Hospitalier Universitaire Méditerranée Infection (IHU Marseille), Vecteurs - Infections tropicales et méditerranéennes (VITROME), and Institut de Recherche pour le Développement (IRD)-Aix Marseille Université (AMU)-Institut de Recherche Biomédicale des Armées [Brétigny-sur-Orge] (IRBA)
- Subjects
Community-Acquired Infections ,Infectious Diseases ,Coxiella burnetii ,Case-Control Studies ,Virology ,[SDV]Life Sciences [q-bio] ,Humans ,Parasitology ,Pneumonia ,Q Fever ,French Guiana ,Retrospective Studies - Abstract
In French Guiana, community-acquired pneumonia (CAP) represents over 90% of Coxiella burnetii acute infections. Between 2004 and 2007, we reported that C. burnetii was responsible for 24.4% of the 131 CAP hospitalized in Cayenne. The main objective of the present study was to determine whether the prevalence of Q fever pneumonia remained at such high levels. The secondary objectives were to identify new clinical characteristics and risk factors for C. burnetii pneumonia. A retrospective case-control study was conducted on patients admitted in Cayenne Hospital, between 2009 and 2012. All patients with CAP were included. The diagnosis of acute Q fever relied on titers of phase II IgG ≥ 200 and/or IgM ≥ 50 or seroconversion between two serum samples. Patients with Q fever were compared with patients with non-C. burnetii CAP in bivariate and multivariate analyses. During the 5-year study, 275 patients with CAP were included. The etiology of CAP was identified in 54% of the patients. C. burnetii represented 38.5% (106/275; 95% CI: 31.2–45.9%). In multivariate analysis, living in Cayenne area, being aged 30–60 years, C-reactive protein (CRP) > 185 mg/L, and leukocyte count < 10 G/L were independently associated with Q fever. The prevalence of Q fever among CAP increased to 38.5%. This is the highest prevalence ever reported in the world. This high prevalence justifies the systematic use of doxycycline in addition to antipneumococcal antibiotic regimens.
- Published
- 2022
- Full Text
- View/download PDF
3. Symptoms and severity in vaccinated and unvaccinated patients hospitalised with SARS-CoV-2 delta (B.1.617.2) variant infection
- Author
-
Olivier Epaulard, Sophie Abgrall, Maeva Lefebvre, Jean-François Faucher, Jocelyn Michon, Emilia Frentiu, Cécile Janssen, Gabrielle Charbonnier, Audrey Fresse, Simon Laurent, Lena Sandjakian, Pierre Casez, Aba Mahamat, and Guillaume Béraud
- Abstract
BackgroundThe diffusion of the SARS-CoV-2 delta (B.1.617.2) variant and the waning of immune response after primary Covid-19 vaccination favoured the breakthrough SARS-CoV-2 infections in vaccinated subjects. To assess the impact of vaccination, we determined the severity of infection in hospitalised patients according to vaccine status.MethodsWe retrospectively analysed data from patients hospitalised in 10 centres with a SARS-CoV-2 infection (delta variant) from July to November 2021: i) all patients who had completed their primary vaccination at least 14 days before hospital admission; and ii) the same number of completely unvaccinated patients. We assessed the impact of vaccination and other risk factors through logistic regression.FindingsWe included 955 patients (474 vaccinated and 481 unvaccinated). Vaccinated patients were significantly older, more frequently males, and with more comorbidities. They were less often admitted for Covid-19 (59·3% vs. 75·1%, pConclusionsAmong patients hospitalised with a delta variant SARS-CoV-2 infection, vaccination was associated with less severe forms, even in the presence of comorbidities.
- Published
- 2022
- Full Text
- View/download PDF
4. Prospective evaluation of the SD BIOLINE Dengue Duo rapid test during a dengue virus epidemic
- Author
-
Mathieu Nacher, Antoine Okandze, Séverine Matheus, F. Djossou, Aba Mahamat, and Christine Simonnet
- Subjects
Adult ,Male ,Microbiology (medical) ,medicine.medical_specialty ,Adolescent ,030231 tropical medicine ,Suspected dengue ,Acute infection ,Viral Nonstructural Proteins ,Dengue virus ,Antibodies, Viral ,medicine.disease_cause ,Sensitivity and Specificity ,Prospective evaluation ,Dengue fever ,Dengue ,Young Adult ,03 medical and health sciences ,0302 clinical medicine ,Internal medicine ,parasitic diseases ,medicine ,Humans ,030212 general & internal medicine ,Child ,Epidemics ,Immunoassay ,business.industry ,Routine laboratory ,Outbreak ,General Medicine ,Dengue Virus ,medicine.disease ,Virology ,Infectious Diseases ,Immunoglobulin M ,Child, Preschool ,Immunoglobulin G ,Female ,Reagent Kits, Diagnostic ,business ,Early phase - Abstract
Dengue virus is endemic in French Guiana with occurrence of cyclical outbreaks. There is a need for rapid tests allowing dengue laboratory diagnosis in healthcare centers scattered throughout this wide Amazonian territory. Our objective was to evaluate the real-life performance of the SD BIOLINE Dengue Duo (IgG/IgM + NS1 Ag) rapid test (RDT) during the 2012-2013 dengue epidemics. The RDT was evaluated in parallel with routine laboratory tests, PlateliaTM Dengue NS1 Ag and Focus Diagnostics Dengue Fever Virus IgM Capture DxSelect. A total of 3,347 patients with suspected dengue acute infection were evaluated. The diagnostic performances of the SD BIOLINE NS1 Ag were equivalent to Platelia NS1, 471 patients (14.1%) were NS1 Ag positive with the RDT and 14.2% with Platelia. The Cohen's Kappa coefficient was 0.86 [95%CI: 0.83-0.88], indicating an almost perfect agreement. Moreover, the sensitivity of SD BIOLINE NS1 Ag relative to the RT-PCR method was 87% [95%CI: 80-93%] and the specificity was 92% [95% CI: 87-97%]. However, the SD BIOLINE IgM test was found positive in 6.3% of the samples in comparison to 10.7% with Dx Select IgM. The Cohen's Kappa coefficient was 0.53 [95%CI: 0.47-0.58] indicating a moderate agreement. This raised concern about the SD BIOLINE IgM for the diagnostic of dengue in endemic areas. When considering only NS1 Ag results and not IgM, the RDT could be a viable solution to manage dengue outbreaks in healthcare centers where no laboratory services are available, in the early phase of the disease.
- Published
- 2017
- Full Text
- View/download PDF
5. Spécificités épidémiologiques de la fièvre Q en Guyane
- Author
-
Sophie Edouard, Jean-Lou Marié, Sébastien Briolant, Félix Djossou, Didier Raoult, Loïc Epelboin, Benoit de Thoisy, Vincent Pommier de Santi, Bernard Davoust, Aba Mahamat, Thierry Lamour, Centre d'épidémiologie et de santé publique des armées, Service de Santé des Armées, Université de Guyane (UG), Unité de Recherche sur les Maladies Infectieuses Tropicales Emergentes (URMITE), Unité de Recherche sur les Maladies Infectieuses et Tropicales Emergentes (URMITE), Institut de Recherche pour le Développement (IRD)-Aix Marseille Université (AMU)-Institut National de la Santé et de la Recherche Médicale (INSERM)-IFR48, INSB-INSB-Centre National de la Recherche Scientifique (CNRS)-Institut de Recherche pour le Développement (IRD)-Aix Marseille Université (AMU)-Institut National de la Santé et de la Recherche Médicale (INSERM)-IFR48, INSB-INSB-Centre National de la Recherche Scientifique (CNRS), Unité de Recherche en Biologie et Epidémiologie Parasitaires, Institut de Médecine Tropicale du Service de Santé des Armées-Centre National de la Recherche Scientifique (CNRS), Centre Hospitalier Andrée Rosemon [Cayenne, Guyane Française], Département des centres de santé, Unité des Maladies Infectieuses et Tropicales (UMIT), Association Kwata (Kwata), Kwata, Institut des sciences biologiques (INSB-CNRS)-Institut des sciences biologiques (INSB-CNRS)-Centre National de la Recherche Scientifique (CNRS)-Institut de Recherche pour le Développement (IRD)-Aix Marseille Université (AMU)-Institut National de la Santé et de la Recherche Médicale (INSERM)-IFR48, and Institut des sciences biologiques (INSB-CNRS)-Institut des sciences biologiques (INSB-CNRS)-Centre National de la Recherche Scientifique (CNRS)
- Subjects
Coxiella burnetii ,épidémiologie ,Guyane ,Fièvre Q ,0301 basic medicine ,General Veterinary ,biology ,[SDV]Life Sciences [q-bio] ,030231 tropical medicine ,biology.organism_classification ,3. Good health ,03 medical and health sciences ,030104 developmental biology ,0302 clinical medicine ,Geography ,[SDV.MHEP.MI]Life Sciences [q-bio]/Human health and pathology/Infectious diseases ,epidemiology ,Q fever ,French Guiana ,Humanities ,ComputingMilieux_MISCELLANEOUS ,[SDV.MHEP]Life Sciences [q-bio]/Human health and pathology - Abstract
Q fever in French Guiana : a specific epidemiological context. During the last 15 years, several studies have been conducted to describe the epidemiology of animal and human Q fever in French Guiana. The main findings highlight disease specificity in this area associated with a unique and hypervirulent strain of Coxiella burnetii, suburban and close to forested area of transmission, pneumonia as primary manifestation of acute Q fever, wild animal reservoir and ticks as putative vector of the bacterium. Prevalence of the disease in French Guianese population remains unknown. A comprehensive health strategy is needed to prevent the disease. We present recent acquired knowledge and outstanding issues, in a “One Health” approach., Les études scientifiques menées sur la fièvre Q en Guyane au cours des quinze dernières années ont permis de répondre à de nombreuses interrogations sur l’épidémiologie humaine et animale de cette maladie. Les résultats observés démontrent une réelle spécificité locale de la fièvre Q, avec une souche de Coxiella burnetii unique et hypervirulente, une transmission suburbaine et en bordure de forêt, principalement sur la ville de Cayenne et ses alentours, des formes pulmonaires prédominantes, un réservoir sauvage de la bactérie et la possibilité d’une transmission vectorielle par les tiques. La prévalence réelle de la maladie dans la population guyanaise reste inconnue et conditionne la mise en oeuvre d’une stratégie de santé publique dédiée. Cette communication se propose de faire une synthèse sur l’ensemble des connaissances acquises et sur les questions qui demeurent, dans une approche One Health., Pommier de Santi Vincent, Marié Jean-Lou, Briolant Sébastien, Mahamat Aba, Djossou Félix, Epelboin Loïc, Lamour Thierry, Thoisy Benoît de, Raoult Didier, Edouard Sophie, Davoust Bernard. Spécificités épidémiologiques de la fièvre Q en Guyane. In: Bulletin de l'Académie Vétérinaire de France tome 169 n°2, 2016. pp. 148-154.
- Published
- 2016
- Full Text
- View/download PDF
6. Q fever epidemic in Cayenne, French Guiana, epidemiologically linked to three-toed sloth
- Author
-
Denis Blanchet, Didier Raoult, Benoit de Thoisy, Jean-Lou Marié, Aba Mahamat, Sophie Edouard, Vincent Pommier de Santi, Carole Ilcinkas, Sébastien Briolant, Georges Hyvert, Bernard Davoust, Yann Reynaud, Vecteurs - Infections tropicales et méditerranéennes (VITROME), Institut de Recherche pour le Développement (IRD)-Aix Marseille Université (AMU)-Institut de Recherche Biomédicale des Armées [Brétigny-sur-Orge] (IRBA), Équipe opérationnelle d’hygiène hospitalière, Centre Hospitalier Andrée Rosemon [Cayenne, Guyane Française], Unité des Maladies Infectieuses et Tropicales (UMIT), Direction Interarmées du Service de Santé [Cayenne, Guyane française], Institut Pasteur de la Guadeloupe, Réseau International des Instituts Pasteur (RIIP), Direction Interarmées du Service de Santé en Guyane, Direction Régionale du Service de Santé des Armées (DRSSA - Toulon), Microbes évolution phylogénie et infections (MEPHI), Institut de Recherche pour le Développement (IRD)-Aix Marseille Université (AMU)-Centre National de la Recherche Scientifique (CNRS), and Institut de Recherche Biomédicale des Armées (IRBA)-Institut de Recherche pour le Développement (IRD)-Aix Marseille Université (AMU)
- Subjects
Adult ,Male ,0301 basic medicine ,Veterinary medicine ,Adolescent ,030231 tropical medicine ,030106 microbiology ,Immunology ,Attack rate ,Three-toed sloth ,Animals, Wild ,Q fever ,Biology ,Real-Time Polymerase Chain Reaction ,Microbiology ,Serology ,Young Adult ,03 medical and health sciences ,0302 clinical medicine ,Risk Factors ,[SDV.MHEP.MI]Life Sciences [q-bio]/Human health and pathology/Infectious diseases ,Zoonoses ,medicine ,Animals ,Humans ,Immunology and Allergy ,Child ,Epidemics ,Feces ,Disease Reservoirs ,Retrospective Studies ,General Veterinary ,Infant ,Outbreak ,General Medicine ,Middle Aged ,biology.organism_classification ,Coxiella burnetii ,medicine.disease ,Sloths ,French Guiana ,3. Good health ,Infectious Diseases ,Child, Preschool ,Female ,Q Fever ,Pneumonia (non-human) - Abstract
International audience; A Q fever epidemic occurred in 2013 in a small military residential area in Cayenne, French Guiana. A retrospective cohort study was conducted to identify Q fever risk factors. Confirmed acute Q fever case was defined as positive serology (IgM >= 50 and phase II IgG >= 200) and/or positive qPCR on serum or blood. In addition, wild mammals were captured at the study site and tested by serology and real-time PCR performed on blood, vaginal swabs and ticks. The attack rate was 20 percent (11/54). All the cases were symptomatic with fever > 38.5 degrees C and community-acquired pneumonia for four cases. Log binomial multivariate models identified two independent risk factors associated with Q fever: to clean the house (RRa = 7.5 CI95% [1.03-55.3]) and to carry a three-toed sloth in arms (RRa = 2.6 CI95% [1.1-5.8]). Eighteen marsupial individuals were captured, all PCRs were negative but 17% (3/18) had a positive serology. Another study conducted after the epidemic found only one (1/4) three-tooth sloth (Bradypus tridactylus) with feces highly infectious for C. burnetii MST17. The same strain C. burnetii genotype 17 has been laboratory-confirmed in this mammal and in human cases. These results support the implication of three-toed-sloth in this epidemic. Human contamination mainly occurs through inhalation of infectious aerosols as suggested by high relative risk associated with house cleaning activities and pulmonary forms of the disease, and through direct contact with three- toed-sloth. Positive serological results among marsupials confirm wildlife exposure and suggest a more complex sylvatic transmission cycle among wild mammals.
- Published
- 2018
- Full Text
- View/download PDF
7. Influence of geographic origin on AIDS and serious non-AIDS morbidity/mortality during cART among heterosexual HIV-infected men and women in France
- Author
-
Laure-Amélie de Monteynard, Sophie Matheron, Sophie Grabar, Pierre de Truchis, Jacques Gilquin, Juliette Pavie, Odile Launay, Jean-Luc Meynard, Marie-Aude Khuong-Josses, David Rey, Aba Mahamat, Rosemarie Dray-Spira, Anne Simon, Dominique Costagliola, Sophie Abgrall, and FHDH-ANRS CO4
- Subjects
lcsh:R ,lcsh:Medicine ,lcsh:Q ,lcsh:Science - Abstract
BACKGROUND:The influence of geographic origin on the risk of severe illness and death on cART has not been explored in European countries. METHOD:We studied antiretroviral-naïve heterosexual HIV-1-infected individuals enrolled in the FHDH-ANRS CO4 cohort in France who started cART between 2006 and 2011. Individuals originating from France (French natives), sub-Saharan Africa (SSA) and non-French West-Indies (NFW) were studied until 2012. Crude and adjusted rate ratios (aRR) of severe morbid events/deaths (AIDS-related and non-AIDS-related) were calculated using Poisson regression models stratified by sex, comparing each group of migrants to French natives. RESULTS:Among 2334 eligible men, 1379 (59.1%) originated from France, 838 (35.9%) from SSA and 117 (5.0%) from NFW. SSA male migrants had a higher aRR for non-AIDS infections, particularly bacterial infections (aRR 1.56 (95% CI 1.07-2.29), p = 0.0477), than French natives. Among 2596 eligible women, 1347 (51.9%) originated from France, 1131 (43.6%) from SSA, and 118 (4.5%) from NFW. SSA and NFW female migrants had a higher aRR for non-AIDS infections, particularly non-bacterial infections (respectively, 2.04 (1.18-3.53) and 7.87 (2.54-24.4), p = 0.0010), than French natives. We observed no other significant differences related to geographic origin as concerns the aRRs for AIDS-related infections or malignancies, or for other non-AIDS events/deaths such as cardiovascular disease, neurological/psychiatric disorders, non-AIDS malignancies and iatrogenic disorders, in either gender. CONCLUSION:Heterosexual migrants from SSA or NFW living in France have a higher risk of non-AIDS-defining infections than their French native counterparts. Special efforts are needed to prevent infectious diseases among HIV-infected migrants.
- Published
- 2018
8. Influence of geographic origin on AIDS and serious non-AIDS morbidity/mortality during cART among heterosexual HIV-infected men and women in France
- Author
-
Laure-Amélie, de Monteynard, Sophie, Matheron, Sophie, Grabar, Pierre, de Truchis, Jacques, Gilquin, Juliette, Pavie, Odile, Launay, Jean-Luc, Meynard, Marie-Aude, Khuong-Josses, David, Rey, Aba, Mahamat, Rosemarie, Dray-Spira, Anne, Simon, Dominique, Costagliola, Sophie, Abgrall, Institut Pierre Louis d'Epidémiologie et de Santé Publique (iPLESP), Sorbonne Université (SU)-Institut National de la Santé et de la Recherche Médicale (INSERM), Infection, Anti-microbiens, Modélisation, Evolution (IAME (UMR_S_1137 / U1137)), Institut National de la Santé et de la Recherche Médicale (INSERM)-Université Paris 13 (UP13)-Université Paris Diderot - Paris 7 (UPD7)-Université Sorbonne Paris Cité (USPC), Services de Maladies Infectieuses et Tropicales [CHU Bichat], AP-HP - Hôpital Bichat - Claude Bernard [Paris], Assistance publique - Hôpitaux de Paris (AP-HP) (AP-HP)-Assistance publique - Hôpitaux de Paris (AP-HP) (AP-HP), Université Sorbonne Paris Cité (USPC), Hôpital Cochin [AP-HP], Assistance publique - Hôpitaux de Paris (AP-HP) (AP-HP), Hôpital Raymond Poincaré [AP-HP], Hôpital Hôtel-Dieu [Paris], Hôpital Européen Georges Pompidou [APHP] (HEGP), Assistance publique - Hôpitaux de Paris (AP-HP) (AP-HP)-Hôpitaux Universitaires Paris Ouest - Hôpitaux Universitaires Île de France Ouest (HUPO), Université Paris Descartes - Paris 5 (UPD5), Services des Maladies Infectieuses et Tropicales [CHU Saint-Antoine], CHU Saint-Antoine [AP-HP], Assistance publique - Hôpitaux de Paris (AP-HP) (AP-HP)-Sorbonne Université (SU)-Assistance publique - Hôpitaux de Paris (AP-HP) (AP-HP)-Sorbonne Université (SU), Hôpital Delafontaine, Centre Hospitalier de Saint-Denis [Ile-de-France], Le Trait d'Union, centre de soins de l'infection par le VIH [CHU Strasbourg], CHU Strasbourg, Unité des Maladies Infectieuses et Tropicales (UMIT), Centre Hospitalier Andrée Rosemon [Cayenne, Guyane Française], Service de médecine interne [CHU Pitié-Salpétrière], Assistance publique - Hôpitaux de Paris (AP-HP) (AP-HP)-CHU Pitié-Salpêtrière [AP-HP], Assistance publique - Hôpitaux de Paris (AP-HP) (AP-HP)-Sorbonne Université (SU)-Sorbonne Université (SU), Hôpital Antoine Béclère, Université Paris-Sud - Paris 11 (UP11)-Assistance publique - Hôpitaux de Paris (AP-HP) (AP-HP), Institut National de la Santé et de la Recherche Médicale (INSERM)-Sorbonne Université (SU), and Université Paris 13 (UP13)-Université Paris Diderot - Paris 7 (UPD7)-Université Sorbonne Paris Cité (USPC)-Institut National de la Santé et de la Recherche Médicale (INSERM)
- Subjects
Adult ,Male ,Risk ,Bacterial Diseases ,European People ,Databases, Factual ,West Indies ,HIV Infections ,Cardiovascular Medicine ,Severity of Illness Index ,Geographical locations ,[SDV.MHEP.MI]Life Sciences [q-bio]/Human health and pathology/Infectious diseases ,Medicine and Health Sciences ,Cardiovascular Diseases in Women ,Humans ,Ethnicities ,Heterosexuals ,Poisson Distribution ,European Union ,French People ,Heterosexuality ,Africa South of the Sahara ,Acquired Immunodeficiency Syndrome ,Incidence ,Middle Aged ,Europe ,Health Care ,Infectious Diseases ,Anti-Retroviral Agents ,Cardiovascular Diseases ,People and Places ,Africa ,Women's Health ,Drug Therapy, Combination ,Female ,Population Groupings ,[SDV.SPEE]Life Sciences [q-bio]/Santé publique et épidémiologie ,France ,Morbidity ,Health Statistics ,Research Article ,Sexuality Groupings - Abstract
International audience; Background: The influence of geographic origin on the risk of severe illness and death on cART has not been explored in European countries.Method: We studied antiretroviral-naïve heterosexual HIV-1-infected individuals enrolled in the FHDH-ANRS CO4 cohort in France who started cART between 2006 and 2011. Individuals originating from France (French natives), sub-Saharan Africa (SSA) and non-French West-Indies (NFW) were studied until 2012. Crude and adjusted rate ratios (aRR) of severe morbid events/deaths (AIDS-related and non-AIDS-related) were calculated using Poisson regression models stratified by sex, comparing each group of migrants to French natives.Results: Among 2334 eligible men, 1379 (59.1%) originated from France, 838 (35.9%) from SSA and 117 (5.0%) from NFW. SSA male migrants had a higher aRR for non-AIDS infections, particularly bacterial infections (aRR 1.56 (95% CI 1.07-2.29), p = 0.0477), than French natives. Among 2596 eligible women, 1347 (51.9%) originated from France, 1131 (43.6%) from SSA, and 118 (4.5%) from NFW. SSA and NFW female migrants had a higher aRR for non-AIDS infections, particularly non-bacterial infections (respectively, 2.04 (1.18-3.53) and 7.87 (2.54-24.4), p = 0.0010), than French natives. We observed no other significant differences related to geographic origin as concerns the aRRs for AIDS-related infections or malignancies, or for other non-AIDS events/deaths such as cardiovascular disease, neurological/psychiatric disorders, non-AIDS malignancies and iatrogenic disorders, in either gender.Conclusion: Heterosexual migrants from SSA or NFW living in France have a higher risk of non-AIDS-defining infections than their French native counterparts. Special efforts are needed to prevent infectious diseases among HIV-infected migrants.
- Published
- 2018
- Full Text
- View/download PDF
9. Effectiveness of postprescription antibiotic stewardship to reduce carbapenem consumption: a quantitative study
- Author
-
B. Moreau, S. Nkouka, P. Abboud, F. Djossou, G. Saint-Lorant, Aba Mahamat, Hatem Kallel, and F. Nkont Cho
- Subjects
0301 basic medicine ,Microbiology (medical) ,Consumption (economics) ,medicine.medical_specialty ,Carbapenem ,business.industry ,030106 microbiology ,Inappropriate Prescribing ,General Medicine ,030501 epidemiology ,Appropriate use ,Drug Prescriptions ,French Guiana ,03 medical and health sciences ,Antimicrobial Stewardship ,Infectious Diseases ,Carbapenems ,medicine ,Antibiotic Stewardship ,Humans ,0305 other medical science ,Intensive care medicine ,business ,medicine.drug ,Program Evaluation - Published
- 2017
10. Salmonella enterica serovar Panama meningitis in exclusive breastfeeding infants: Report of 4 cases, clinical features and therapeutic challenges
- Author
-
Rémi Kom-Tchameni, Falucar Njuieyon, Fanny Henaff, Emma Cuadro, Sitraka Herinantenaina Razafindrakoto, Laurence Long, Antoine Defo, Yajaira Mrsic, Narcisse Elenga, Aba Mahamat, and Elise Martin
- Subjects
0301 basic medicine ,Serotype ,Male ,Pediatrics ,medicine.medical_specialty ,030106 microbiology ,Salmonella panama ,Breastfeeding ,Salmonella infection ,Meningitis, Bacterial ,03 medical and health sciences ,0302 clinical medicine ,030225 pediatrics ,case reports ,medicine ,Humans ,Clinical Case Report ,biology ,business.industry ,Infant ,Salmonella enterica ,meningitis ,General Medicine ,biology.organism_classification ,medicine.disease ,Hydrocephalus ,Diarrhea ,Breast Feeding ,Early Diagnosis ,exclusive breastfeeding ,Immunology ,Salmonella Infections ,Female ,medicine.symptom ,business ,Meningitis ,Breast feeding ,Research Article - Abstract
Rationale: The pathway of Nontyphoid Salmonella meningitis, especially in exclusive breastfeeding infants, has not been well characterized. Patient concerns: We analyzed data related to nontyphoid Salmonella meningitis in 4 infants. Diagnoses: No diarrhea was observed and the coproculture was negative for all patients. Interventions: Early diagnosis and treatment with combination of third-generation cephalosporins plus quinolones for a minimum of 3 weeks is necessary to avoid severe sequelae and death. Outcomes: The first 3 patients had a good evolution, whereas the last patient had multiple brain abscesses and hydrocephalus requiring treatment with a ventriculoperitoneal shunt. Lessons: The highlights of our study are that all infants were exclusively breastfed, no diarrhea observed and the negative coproculture for all the 4 patients, which is relatively rare for Salmonella infection.
- Published
- 2017
11. Significant Reduction in HIV Virologic Failure During a 15-Year Period in a Setting With Free Healthcare Access
- Author
-
Murielle Mary-Krause, Boue F, Christian Pradier, Laurence Lievre, Eric Billaud, Jacques Reynes, Laurent Cotte, O. Launay, Hervé Tissot-Dupont, M. A. Khuong, D. Martin, Constance Delaugerre, Elisabeth Rouveix, D. Costagliola, E. Salat, Sophie Grabar, Hana Selinger-Leneman, C. Bronnec, Jean-Paul Viard, Laurent Boyer, F. Barin, Sophie Matheron, Pierre de Truchis, Marguerite Guiguet, Lise Cuzin, N. Viget, Aba Mahamat, J. M. Lacombe, Lionel Piroth, Odile Launay, A. Simon, Valérie Potard, Jean-Marc Lacombe, P. De Truchis, Jacques Gilquin, André Cabié, Amélie Menard, J. Le Bail, Jean-Luc Meynard, Sophie Abgrall, Pierre Tattevin, Fabienne Caby, Juliette Pavie, S. Lang, Patricia Enel, Jade Ghosn, Jacques Gasnault, C. Gaud, Xavier Duval, Isabelle Poizot-Martin, Dominique Costagliola, Gilles Pialoux, and Claudine Duvivier
- Subjects
Adult ,Male ,Microbiology (medical) ,medicine.medical_specialty ,Anti-HIV Agents ,Human immunodeficiency virus (HIV) ,Integrase inhibitor ,HIV Infections ,Logistic regression ,medicine.disease_cause ,Health Services Accessibility ,Internal medicine ,Health care ,medicine ,Humans ,Cd4 cell count ,Stage (cooking) ,Generalized estimating equation ,business.industry ,Disease Management ,HIV ,Middle Aged ,Surgery ,VIROLOGIC FAILURE ,Treatment Outcome ,Infectious Diseases ,RNA, Viral ,Female ,business - Abstract
Background. Calendar trends in virologic failure (VF) among human immunodeficiency virus (HIV)-infected patients can help to evaluate the performance of healthcare systems and the need for new antiretroviral therapy (ART). We examined the time trend in the rate of VF beyond 6 months of ART between 1997 and 2011 in France. Methods. We included patients from the French Hospital Database on HIV who received at least 6 months of ART. VF was defined as 2 consecutive plasma HIV-RNA values >500 copies/mL or as 1 value >500 copies/mL followed byatreatment switch. We adjusted for patients’ characteristics by fitting a multivariable generalized estimating equation logistic regression model with an exchangeable covariance matrix. Results. A total of 81738 patients were enrolled, and median follow-up was 112.4 months. Median CD4 count was 333 cells/µL, and 23% of patients had HIV infection classified as Centers for Disease Control and Prevention stage C. Overall, 29.3% of patients received single/dual-drug ART initially, and 45.4% of patients experienced at least 1 episode of VF during follow-up. The percentage of patients with VF fell from 61.5% in 1997–1998 to 9.7% in 2009–2011 (P
- Published
- 2014
- Full Text
- View/download PDF
12. Q Fever in French Guiana
- Author
-
Philippe Abboud, Carole Eldin, Félix Djossou, Magalie Demar, Didier Raoult, and Aba Mahamat
- Subjects
Disease reservoir ,medicine.medical_specialty ,Genotype ,Q fever ,Context (language use) ,Biology ,Communicable Diseases, Emerging ,Environmental protection ,Virology ,parasitic diseases ,Epidemiology ,Prevalence ,medicine ,Animals ,Humans ,Disease Reservoirs ,Mortality rate ,Public health ,Articles ,medicine.disease ,Coxiella burnetii ,biology.organism_classification ,French Guiana ,Infectious Diseases ,Parasitology ,Q Fever ,Pneumonia (non-human) ,Demography - Abstract
Coxiella burnetii, the causative agent of Q fever, is present worldwide. Recent studies have shown that this bacterium is an emerging pathogen in French Guiana and has a high prevalence (24% of community-acquired pneumonia). In this review, we focus on the peculiar epidemiology of Q fever in French Guiana. We place it in the context of the epidemiology of the disease in the surrounding countries of South America. We also review the clinical features of Q fever in this region, which has severe initial presentation but low mortality rates. These characteristics seem to be linked to a unique genotype (genotype 17). Finally, we discuss the issue of the animal reservoir of C. burnetii in French Guiana, which is still unknown. Further studies are necessary to identify this reservoir. Identification of this reservoir will improve the understanding of the Q fever epidemic in French Guiana and will provide new tools to control this public health problem.
- Published
- 2014
- Full Text
- View/download PDF
13. Comparison between Emerging Q Fever in French Guiana and Endemic Q fever in Marseille, France
- Author
-
Sophie Edouard, Didier Raoult, Félix Djossou, Magalie Demar, Philippe Abboud, and Aba Mahamat
- Subjects
Adult ,DNA, Bacterial ,Male ,medicine.medical_specialty ,Veterinary medicine ,Cardiovascular infection ,Adolescent ,Endemic Diseases ,Q fever ,Communicable Diseases, Emerging ,Gastroenterology ,Serology ,Young Adult ,Risk Factors ,Virology ,Internal medicine ,Epidemiology ,Prevalence ,medicine ,Humans ,Endocarditis ,Aged ,Retrospective Studies ,Aged, 80 and over ,biology ,business.industry ,Incidence ,Incidence (epidemiology) ,Articles ,Middle Aged ,medicine.disease ,Coxiella burnetii ,biology.organism_classification ,French Guiana ,Pneumonia ,Infectious Diseases ,Cardiovascular Diseases ,Immunoglobulin G ,Acute Disease ,Female ,Parasitology ,France ,Q Fever ,business - Abstract
Q fever is an emergent disease in French Guiana. We compared the incidence clinical and serologic profiles between patients from Cayenne, French Guiana and Marseille in metropolitan France during a four-year period. The annual incidence of diagnosed acute Q fever was significantly higher in Cayenne (17.5/100,000) than in Marseille (1.9/100,000) (P = 0.0004), but not the annual incidence of endocarditis (1.29 versus 0.34/100,000). Most patients had fever (97%) and pneumonia (83%) in Cayenne versus 81% and 8% in Marseille (P < 0.0001 and P < 0.0001, respectively) but transaminitis was more common in patients from Marseille (54% versus 32%; P < 0.0001). The proportion of patients with cardiovascular infections was significantly lower in Cayenne (7%) than in Marseille (17%) (P = 0.017), although they showed a stronger immune response with higher levels of phase I IgG (P = 0.024). The differing epidemiology, clinical, and serologic responses of patients from Cayenne and Marseille suggest a different source of infection and a different strain of Coxiella burnetii.
- Published
- 2014
- Full Text
- View/download PDF
14. Cohort Profile: French hospital database on HIV (FHDH-ANRS CO4)
- Author
-
Claudine Duvivier, Laurence Lievre, Lionel Piroth, Jacques Gasnault, Murielle Mary-Krause, Sophie Grabar, Jacques Gilquin, N. Viget, Anne Simon, Laurent Cotte, Isabelle Poizot-Martin, Valérie Potard, André Cabié, Hervé Tissot-Dupont, Sophie Abgrall, Christian Pradier, Anne-Sophie Lascaux, Eric Billaud, Jean-Marc Lacombe, Juliette Pavie, Marie-Aude Khuong-Josses, Laurence Boyer, François Boué, Jacques Reynes, Patricia Enel, Sophie Matheron, Sylvie Lang, Aba Mahamat, Hana Selinger-Leneman, Pierre de Truchis, Christine Katlama, Fabrice Pilorgé, Pierre Tattevin, Dominique Costagliola, Jean-Luc Meynard, Marguerite Guiguet, Odile Launay, C. Gaud, Xavier Duval, Jean-Paul Viard, Elisabeth Rouveix, Institut Pierre Louis d'Epidémiologie et de Santé Publique (iPLESP), Institut National de la Santé et de la Recherche Médicale (INSERM)-Sorbonne Université (SU), Université Pierre et Marie Curie - Paris 6 (UPMC), AP-HP - Hôpital Cochin Broca Hôtel Dieu [Paris], Assistance publique - Hôpitaux de Paris (AP-HP) (AP-HP), Université Paris Descartes - Paris 5 (UPD5), Hôpital Avicenne [AP-HP], Centre hospitalier universitaire de Nantes (CHU Nantes), AP-HP - Hôpital Antoine Béclère [Clamart], Centre Hospitalier Régional Universitaire de Nancy (CHRU Nancy), CHU de la Martinique [Fort de France], Centre de Recherche en Cancérologie de Lyon (UNICANCER/CRCL), Centre Léon Bérard [Lyon]-Université Claude Bernard Lyon 1 (UCBL), Université de Lyon-Université de Lyon-Institut National de la Santé et de la Recherche Médicale (INSERM)-Centre National de la Recherche Scientifique (CNRS), Hôpital de la Croix-Rousse [CHU - HCL], Hospices Civils de Lyon (HCL), Hôpital Raymond Poincaré [AP-HP], AP-HP - Hôpital Bichat - Claude Bernard [Paris], Centre Médical de l'Institut Pasteur (CMIP), Institut Pasteur [Paris] (IP), Centre d'infectiologie Necker-Pasteur [CHU Necker], Institut Pasteur [Paris] (IP)-CHU Necker - Enfants Malades [AP-HP], Assistance publique - Hôpitaux de Paris (AP-HP) (AP-HP)-Assistance publique - Hôpitaux de Paris (AP-HP) (AP-HP), FHDH is supported by the ANRS, INSERM and the FrenchMinistry of Health., Sorbonne Université (SU)-Institut National de la Santé et de la Recherche Médicale (INSERM), Institut Pasteur [Paris], Institut Pasteur [Paris]-CHU Necker - Enfants Malades [AP-HP], Malbec, Odile, Centre Médical de l'Institut Pasteur, CHU Necker - Enfants Malades [AP-HP], and Assistance publique - Hôpitaux de Paris (AP-HP) (AP-HP)-Assistance publique - Hôpitaux de Paris (AP-HP) (AP-HP)-Institut Pasteur [Paris]
- Subjects
Adult ,Male ,antiretroviral treatment ,medicine.medical_specialty ,Databases, Factual ,Epidemiology ,[SDV]Life Sciences [q-bio] ,HIV Infections ,Context (language use) ,comorbidities ,computer.software_genre ,Hepatitis ,Cohort Studies ,03 medical and health sciences ,0302 clinical medicine ,Acquired immunodeficiency syndrome (AIDS) ,Risk Factors ,Informed consent ,Antiretroviral Therapy, Highly Active ,medicine ,Humans ,030212 general & internal medicine ,Cause of death ,Acquired Immunodeficiency Syndrome ,0303 health sciences ,Database ,Coinfection ,030306 microbiology ,business.industry ,Medical record ,Public health ,HIV ,cohort ,General Medicine ,Middle Aged ,medicine.disease ,Hospitals ,3. Good health ,[SDV] Life Sciences [q-bio] ,AIDS ,Cohort ,Female ,France ,business ,FHDH ,computer - Abstract
International audience; The French Hospital Database on HIV (FHDH) is a hospital-based multicentre open cohort with inclusions ongoing since 1989. The research objectives focus mainly on mid- and long-term clinical outcomes and therapeutic strategies, as well as severe AIDS and non-AIDS morbidities, and public health issues relative to HIV infection. FHDH also serves to describe HIV-infected patients receiving hospital care in France. FHDH includes data on more than 120,000 HIV-infected patients from 70 French general or university hospitals distributed throughout France. Patients are eligible for inclusion if they are infected by HIV-1 or HIV-2 and give their written informed consent. Standardized variables are collected at each outpatient visit or hospital admission during which a new clinical manifestation is diagnosed, a new treatment is prescribed or a change in biological markers is noted, and/or at least every 6 months. Since its inception, variables collected in FHDH include demographic characteristics, HIV-related biological markers, the date and type of AIDS and non AIDS-defining events, antiretroviral treatments and the date and causes of death, as reported in the medical records. Since 2005, data have also been collected on: co-infection with hepatitis B or C virus; alcohol and tobacco use; and non HIV-related biomarkers. Anyone can submit a research project by completing a standardized form available on the FHDH website (http://www.ccde.fr/_fold/fl-1385734776-429.pdf) or from the corresponding author, describing the context and objectives of the study. All projects are reviewed by the scientific committee.
- Published
- 2014
- Full Text
- View/download PDF
15. Antibiotic susceptibility determination for six strains of Coxiella burnetii MST 17 from Cayenne, French Guiana
- Author
-
Carole Eldin, Céline Perreal, Didier Raoult, F. Djossou, Aba Mahamat, and Sophie Edouard
- Subjects
Microbiology (medical) ,Cayenne ,Genotype ,medicine.drug_class ,Antibiotics ,Q fever ,Microbial Sensitivity Tests ,Microbiology ,Molecular typing ,medicine ,Humans ,Pharmacology (medical) ,computer.programming_language ,biology ,General Medicine ,Flow Cytometry ,Coxiella burnetii ,biology.organism_classification ,medicine.disease ,Virology ,Anti-Bacterial Agents ,French Guiana ,Molecular Typing ,Infectious Diseases ,Q Fever ,computer - Published
- 2015
- Full Text
- View/download PDF
16. Rainfall and Sloth Births in May, Q Fever in July, Cayenne, French Guiana
- Author
-
Félix Djossou, Didier Raoult, Aba Mahamat, and Carole Eldin
- Subjects
Wet season ,Veterinary medicine ,Disease reservoir ,Cayenne ,Rain ,Q fever ,Virology ,biology.animal ,parasitic diseases ,medicine ,Animals ,Humans ,Disease Reservoirs ,computer.programming_language ,biology ,Ecology ,Incidence ,Incidence (epidemiology) ,Articles ,Sloth ,medicine.disease ,Coxiella burnetii ,biology.organism_classification ,Sloths ,French Guiana ,Infectious Diseases ,Parasitology ,Seasons ,Q Fever ,computer - Abstract
Q fever in French Guiana is correlated with the rainy season. We found a 1- to 2-month lagged correlation between Q fever incidence and the number of births of three-toed sloth. This result strengthens the hypothesis that the three-toed sloth is the wild reservoir of Q fever in French Guiana.
- Published
- 2015
- Full Text
- View/download PDF
17. Additive preventive effect of influenza and pneumococcal vaccines in the elderly
- Author
-
Jean-Pierre Daurès, Benoît de Wazières, and Aba Mahamat
- Subjects
Male ,Pediatrics ,medicine.medical_specialty ,medicine.drug_class ,Influenza vaccine ,Immunology ,Antibiotics ,Pneumococcal Infections ,Cohort Studies ,Pneumococcal Vaccines ,Influenza, Human ,medicine ,Humans ,Immunology and Allergy ,Aged ,Aged, 80 and over ,Pharmacology ,business.industry ,Mortality rate ,Incidence (epidemiology) ,medicine.disease ,Survival Analysis ,Drug Utilization ,Anti-Bacterial Agents ,Vaccination ,Pneumococcal infections ,Pneumococcal vaccine ,Influenza Vaccines ,Female ,France ,business ,Research Paper ,Cohort study - Abstract
Elderly people are at increased risk of influenza and pneumococcal diseases. Influenza increases clinical pneumococcal disease incidence. Pneumococcal vaccination could therefore be a supplement to influenza vaccination. This study evaluated all-cause mortality and antibiotic consumption according to elderly people’s influenza and pneumococcal vaccination status. Its goal was to demonstrate that vaccination with both Influenza and pneumococcal vaccines decrease all-cause mortality and antibiotic consumption. From 2004-10-01 to 2004-12-31 (3 mo), elderly people (≥ 65 y) who lived in the Gard department (South of France) were offered both vaccinations. Among the 68,897 subjects followed-up one year after this vaccination campaign, 21,303 (30.9%) were vaccinated with both vaccines, 18,651 (27.1%) with influenza vaccine alone, 3,769 (5.5%) with pneumococcal vaccine alone; 25,174 (36.5%) subjects were unvaccinated. Mortality rate (per 1,000 inhabitants-year) adjusted on gender, age and prior underlying chronic disease was 17.9 (95% CI: 16.3–19.6), 20.8 (19.0–22.8), 22.5 (19.0–26.6) and 24.7 (22.7–26.8), respectively. It was 42.1 (38.8–45.8) in elderly people with underlying chronic disease who received both vaccines vs. 58.1 (53.7–62.9) in unvaccinated elderly people. The decrease in mortality rate was 27.0% (20.0–34.0) in subjects who received both vaccines and 16.0% (6.0–24.0) in those who received influenza vaccine. No significant reduction in mortality rate was seen with the pneumococcal vaccine alone. Influenza and/or pneumococcal vaccinations did not decrease antibiotic consumption that drastically increases during the winter period. An additive effect was observed in the prevention of all-cause mortality with influenza and pneumococcal vaccines given together in elderly people, including in those with underlying chronic disease.
- Published
- 2013
- Full Text
- View/download PDF
18. A predictive score for hypotension in patients with confirmed dengue fever in Cayenne Hospital, French Guiana
- Author
-
Magalie Demar, Guillaume Vesin, Philippe Abboud, Denis Malvy, Narcisse Elenga, Loïc Epelboin, G. Walter, Mathieu Nacher, Félix Djossou, Thierry Le-Guen, Dominique Rousset, Aba Mahamat, B. Moreau, Unité des Maladies Infectieuses et Tropicales (UMIT), Centre Hospitalier Andrée Rosemon [Cayenne, Guyane Française], EA 3593 Université des Antilles et de la Guyane, Service de Pédiatrie, Centre Hospitalier Andrée Rosemon [Cayenne, Guyane Française]-Centre Hospitalier Andrée Rosemon [Cayenne, Guyane Française], Unité des Maladies Infectieuses et Tropicales [Cayenne, Guyane Française], Unité des Maladies Infectieuses et Tropicales [Cayenne, Guyanne Française], Institut pluridisciplinaire de recherche appliquée dans le domaine du génie pétrolier (IPRADDGP), Université de Pau et des Pays de l'Adour (UPPA)-Centre National de la Recherche Scientifique (CNRS), Mer, molécules et santé EA 2160 (MMS), Le Mans Université (UM)-Université de Nantes - UFR des Sciences Pharmaceutiques et Biologiques, Université de Nantes (UN)-Université de Nantes (UN), Coordination Régionale de la lutte contre l'infection due au VIH (COREVIH), COREVIH, Coordination Régionale de la lutte contre le Virus de L'Immunodéficience Humaine (COREVIH Guyane), Service de médecine interne et maladies tropicales, CHU Bordeaux [Bordeaux]-Groupe hospitalier Saint-André, Medicine Department, Ecosystemes Amazoniens et Pathologie Tropicale (EPat), Institut National de la Santé et de la Recherche Médicale (INSERM)-Université de Guyane (UG)-Institut National de la Santé et de la Recherche Médicale (INSERM)-Université de Guyane (UG), Université de Guyane (UG), Institut Pasteur de la Guyane, Réseau International des Instituts Pasteur (RIIP), Institut de l’Élevage, Équipe opérationnelle d’hygiène hospitalière, Epidémiologie et Biostatistique [Bordeaux], Université Bordeaux Segalen - Bordeaux 2-Institut de Santé Publique, d'Épidémiologie et de Développement (ISPED)-Institut National de la Santé et de la Recherche Médicale (INSERM), Centre d'investigation clinique Antilles-Guyane (CIC - Antilles Guyane), and Institut National de la Santé et de la Recherche Médicale (INSERM)-CHU de la Martinique [Fort de France]-CHU Pointe-à-Pitre/Abymes [Guadeloupe] -Centre Hospitalier Andrée Rosemon [Cayenne, Guyane Française]
- Subjects
Male ,Low protein ,[SDV]Life Sciences [q-bio] ,Hematocrit ,Dengue fever ,Dengue ,0302 clinical medicine ,[SDV.MHEP.MI]Life Sciences [q-bio]/Human health and pathology/Infectious diseases ,Longitudinal Studies ,030212 general & internal medicine ,Child ,ComputingMilieux_MISCELLANEOUS ,[SDV.MHEP.ME]Life Sciences [q-bio]/Human health and pathology/Emerging diseases ,Framingham Risk Score ,medicine.diagnostic_test ,Incidence ,Incidence (epidemiology) ,Age Factors ,General Medicine ,Middle Aged ,Prognosis ,Rash ,3. Good health ,French Guiana ,Infectious Diseases ,Child, Preschool ,[SDV.MP.VIR]Life Sciences [q-bio]/Microbiology and Parasitology/Virology ,Female ,medicine.symptom ,Hypotension ,Adult ,medicine.medical_specialty ,Adolescent ,030231 tropical medicine ,Young Adult ,03 medical and health sciences ,Predictive Value of Tests ,Internal medicine ,medicine ,Humans ,Epidemics ,Purpura ,Proportional Hazards Models ,Proportional hazards model ,business.industry ,Predictors ,Protein ,Public Health, Environmental and Occupational Health ,Infant ,[SDV.BBM.BM]Life Sciences [q-bio]/Biochemistry, Molecular Biology/Molecular biology ,Exanthema ,medicine.disease ,Surgery ,Longitudinal ,Parasitology ,[SDV.SPEE]Life Sciences [q-bio]/Santé publique et épidémiologie ,business ,[SDV.MHEP]Life Sciences [q-bio]/Human health and pathology ,Low sodium - Abstract
Background Identifying patients at risk of developing severe dengue is challenging. The objective of the present study was to determine the incidence of hypotension and its predictive factors during the Dengue 2 epidemic in 2013. Methods In 2013, a longitudinal study was performed using data from all confirmed cases of dengue seen in Cayenne General Hospital. The analysis used Cox proportional modeling to obtain adjusted hazards ratios for hypotension. Results A total of 806 confirmed patients were included 78 (9.6%) of whom developed hypotension. Extensive purpura, cutaneomucous hemorrhage, serous effusion and age 1-15 years were associated with subsequent hypotension whereas 'aches' and a rash were associated with a lower incidence of hypotension. The biological variables independently associated with hypotension were: increase of hematocrit, low protein concentrations, low sodium concentration and lymphocytes over 1400/ml. A risk score was computed from the scaled Cox model coefficient. Conclusions From a clinician's perspective, extensive purpura, cutaneomucous hemorrhage, serous effusion, age 1-15 years, hematocrit increase, low protein, low sodium, lymphocytosis and the absence of aches or of a rash, may be important warning signs to predict subsequent hypotension and shock. Over half of the patients with the highest risk score subsequently developed hypotension. The prognostic score had a 48.2% sensitivity with less than 10% of false positives. This score requires external validation before its impact on clinical practice is evaluated.
- Published
- 2016
- Full Text
- View/download PDF
19. Q Fever in French Guiana: Tip of the Iceberg or Epidemiological Exception?
- Author
-
Carole Eldin, Magalie Pierre-Demar, Emilie Mosnier, Sébastien Briolant, Aba Mahamat, Alain Berlioz-Arthaud, Mathieu Nacher, Elba Regina Sampaio de Lemos, Didier Raoult, Philippe Abboud, Loïc Epelboin, Marcus V. G. Lacerda, Vincent Pommier de Santi, Félix Djossou, Margarete do Socorro Mendonça Gomes, Stephen Vreden, Unité des Maladies Infectieuses et Tropicales (UMIT), Centre Hospitalier Andrée Rosemon [Cayenne, Guyane Française], Université de Guyane (UG), Ecosystemes Amazoniens et Pathologie Tropicale (EPat), Institut National de la Santé et de la Recherche Médicale (INSERM)-Université de Guyane (UG), Centre d'épidémiologie et de santé publique des armées, Service de Santé des Armées, Institut Pasteur de la Guyane, Réseau International des Instituts Pasteur (RIIP), Vecteurs - Infections tropicales et méditerranéennes (VITROME), Institut de Recherche pour le Développement (IRD)-Aix Marseille Université (AMU)-Institut de Recherche Biomédicale des Armées [Brétigny-sur-Orge] (IRBA), Laboratorio Central de Saude Publica do Amapa, Hospital de Clinicas Dr. Alberto Lima, Academisch Ziekenhuis Paramaribo Hospital, Fundação de Medicina Tropical Doutor Heitor Vieira Dourado (FMT-HVD), Unité de Recherche sur les Maladies Infectieuses et Tropicales Emergentes (URMITE), Institut de Recherche pour le Développement (IRD)-Aix Marseille Université (AMU)-Institut National de la Santé et de la Recherche Médicale (INSERM)-IFR48, Institut des sciences biologiques (INSB-CNRS)-Institut des sciences biologiques (INSB-CNRS)-Centre National de la Recherche Scientifique (CNRS), Fundação Oswaldo Cruz / Oswaldo Cruz Foundation (FIOCRUZ), The authors received no specific funding for this work., Institut de Recherche pour le Développement (IRD)-Aix Marseille Université (AMU)-Institut de Recherche Biomédicale des Armées (IRBA), INSB-INSB-Centre National de la Recherche Scientifique (CNRS), Fundação Oswaldo Cruz (FIOCRUZ), Institut de Recherche Biomédicale des Armées (IRBA)-Institut de Recherche pour le Développement (IRD)-Aix Marseille Université (AMU), Unité des Maladies Infectieuses et Tropicales ( UMIT ), Ecosystemes Amazoniens et Pathologie Tropicale ( EPat ), Institut National de la Santé et de la Recherche Médicale ( INSERM ) -Université de Guyane ( UG ), Coordination Régionale de la lutte contre le Virus de L'Immunodéficience Humaine ( COREVIH ), Centre d'investigation clinique Antilles-Guyane ( CIC - Antilles Guyane ), Institut National de la Santé et de la Recherche Médicale ( INSERM ) -CHU de la Martinique-CHU Pointe-à-Pitre/Abymes [Guadeloupe] -Centre Hospitalier Andrée Rosemon [Cayenne, Guyane Française], Équipe opérationnelle d’hygiène hospitalière, Direction Interarmées du Service de Santé en Guyane, Réseau International des Instituts Pasteur ( RIIP ), Unité de Recherche sur les Maladies Infectieuses et Tropicales Emergentes ( URMITE ), Institut de Recherche pour le Développement ( IRD ) -Aix Marseille Université ( AMU ) -Institut National de la Santé et de la Recherche Médicale ( INSERM ) -IFR48, INSB-INSB-Centre National de la Recherche Scientifique ( CNRS ), Département des Centres Délocalisés de Prévention et de Soins, Academisch Ziekenhuis, Paramaribo Hospital, Fundação de Medicina Tropical Doutor Heitor Vieira Dourado ( FMT-HVD ), Instituto Leônidas e Maria Deane ( ILMD ), Instituto Oswaldo Cruz / Fiocruz, Institut Hospitalier Universitaire Méditerranée Infection ( IHU AMU ), and Latour, Marie
- Subjects
0301 basic medicine ,Bacterial Diseases ,Latin Americans ,Pulmonology ,Pathology and Laboratory Medicine ,Communicable Diseases, Emerging ,Geographical locations ,0302 clinical medicine ,Environmental protection ,[SDV.MHEP.MI]Life Sciences [q-bio]/Human health and pathology/Infectious diseases ,Zoonoses ,Medicine and Health Sciences ,MESH: Animals ,MESH: Communicable Diseases, Emerging ,[SDV.MHEP.ME] Life Sciences [q-bio]/Human health and pathology/Emerging diseases ,[SDV.MHEP.ME]Life Sciences [q-bio]/Human health and pathology/Emerging diseases ,biology ,Endocarditis ,Amazon rainforest ,Incidence (epidemiology) ,lcsh:Public aspects of medicine ,Zoonosis ,Neglected Diseases ,[ SDV.SPEE ] Life Sciences [q-bio]/Santé publique et épidémiologie ,3. Good health ,French Guiana ,Bacterial Pathogens ,Viewpoints ,Geography ,Infectious Diseases ,Medical Microbiology ,[SDV.MHEP.MI] Life Sciences [q-bio]/Human health and pathology/Infectious diseases ,Ecuador ,Pathogens ,Q Fever ,MESH: Zoonoses ,Coxiella Burnetii ,Brazil ,lcsh:Arctic medicine. Tropical medicine ,MESH: Q Fever ,lcsh:RC955-962 ,030106 microbiology ,030231 tropical medicine ,Cardiology ,Q fever ,Colombia ,Microbiology ,03 medical and health sciences ,parasitic diseases ,MESH: French Guiana ,medicine ,Seroprevalence ,Animals ,Humans ,Microbial Pathogens ,Mexico ,MESH: Humans ,Public Health, Environmental and Occupational Health ,Outbreak ,Biology and Life Sciences ,lcsh:RA1-1270 ,Pneumonia ,South America ,medicine.disease ,Coxiella burnetii ,biology.organism_classification ,[SDV.SPEE] Life Sciences [q-bio]/Santé publique et épidémiologie ,North America ,[SDV.SPEE]Life Sciences [q-bio]/Santé publique et épidémiologie ,People and places ,MESH: Neglected Diseases ,Demography - Abstract
International audience; Q fever is a cosmopolitan zoonosis caused by an intracellular bacterium, Coxiella burnetii. Since its discovery in 1935 in Australia, its presence has been reported almost worldwide in animals and humans [1]. In most developed countries, this infection has been widely described, and its life cycle, exposure factors, and clinical and biological pictures are well known. The incidence of Q fever is generally quite low, and most of the cases are diagnosed during short outbreaks related to direct or indirect contact of humans with cattle, sheep, or goats, which are the main reservoirs. In developing countries, information on endemicity is generally scarce and limited to seroprevalence studies in exposed populations or case reports. This presumably reflects misdiagnosis, rather than lower incidence. The diagnosis of acute Q fever mostly relies on the elevation of anti-C. burnetii antibodies by 15 to 21 days after the onset of the symptoms, detected by Immunofluorescence Assay, which is the gold standard for C. burnetii detection. However, these diagnostic techniques are often not available in tropical areas and, apparently, in numerous Latin American settings. Indeed, an exhaustive review of the literature in English, French, Spanish, and Portuguese showed that publications on Q fever in Latin America are scarce despite the worldwide presence of the disease (Table 1). Seven countries have never reported any cases of Q fever according to the available literature (Belize, Costa Rica, Guatemala, Guyana, Honduras, Paraguay, Suriname); three haven't reported any since 1990, but some older studies do exist (Bolivia, Pan-ama, Venezuela); seven countries reported one or two publications since 1990 (Argentina, Chile, Ecuador, El Salvador, Peru, Trinidad, Uruguay); and Colombia, Mexico, and Brazil published several publications, including mostly case reports of chronic Q fever, one case of acute Q fever, several seroprevalence studies in exposed populations, and some studies based on an acute febrile or acute respiratory syndrome approach. Recently, Q fever was confirmed in patients and animals in parts of the Brazilian Atlantic Forest. Thus, there are no publications on Q fever in the Amazon region except in French Guiana and Ecuador.
- Published
- 2016
- Full Text
- View/download PDF
20. Clinical epidemiology and resistance mechanisms of carbapenem-resistant Acinetobacter baumannii, French Guiana, 2008-2014
- Author
-
Magalie Demar, Pierre Couppié, Hatem Kallel, Mathieu Nacher, Christine Simonnet, Didier Hommel, Félix Djossou, Aba Mahamat, Xavier Bertrand, B. Moreau, Centre Hospitalier Régional Universitaire [Besançon] ( CHRU Besançon ), Laboratoire Chrono-environnement ( LCE ), Université Bourgogne Franche-Comté ( UBFC ) -Centre National de la Recherche Scientifique ( CNRS ) -Université de Franche-Comté ( UFC ), Institut de l’Élevage, Centre Hospitalier Andrée-Rosemond, Epidemiologie des Parasitoses Tropicales ( EPaT Team ), Université des Antilles et de la Guyane ( UAG ) -Institut National de la Santé et de la Recherche Médicale ( INSERM ), Centre Hospitalier Andrée Rosemon [Cayenne, Guyane Française], Département de Biologie, Unité de Biochimie des Lipides et des Protéines, Faculté des Sciences de Tunis, Ecosystemes Amazoniens et Pathologie Tropicale ( EPat ), Université de Guyane ( UG ) -Institut Pasteur de la Guyane, Réseau International des Instituts Pasteur ( RIIP ) -Réseau International des Instituts Pasteur ( RIIP ) -Institut National de la Santé et de la Recherche Médicale ( INSERM ), Laboratoire Hospitalo-Universitaire de Parasitologie-Mycologie, Coordination Régionale de la lutte contre le Virus de L'Immunodéficience Humaine (COREVIH)-Centre Hospitalier Andrée Rosemon [Cayenne, Guyane Française]-Université des Antilles ( UA ), Unité des Maladies Infectieuses et Tropicales [Cayenne, Guyanne Française], Centre d'investigation clinique Antilles-Guyane ( CIC - Antilles Guyane ), Institut National de la Santé et de la Recherche Médicale ( INSERM ) -CHU Pointe-à-Pitre/Abymes [Guadeloupe] -CHU de la Martinique-Centre Hospitalier Andrée Rosemon [Cayenne, Guyane Française], Coordination Régionale de la lutte contre le Virus de L'Immunodéficience Humaine ( COREVIH Guyane ), Centre Hospitalier Régional Universitaire de Besançon (CHRU Besançon), Laboratoire Chrono-environnement - CNRS - UBFC (UMR 6249) (LCE), Centre National de la Recherche Scientifique (CNRS)-Université de Franche-Comté (UFC), Université Bourgogne Franche-Comté [COMUE] (UBFC)-Université Bourgogne Franche-Comté [COMUE] (UBFC), Ecosystemes Amazoniens et Pathologie Tropicale (EPat), Institut National de la Santé et de la Recherche Médicale (INSERM)-Université de Guyane (UG), Faculté des Sciences Mathématiques, Physiques et Naturelles de Tunis (FST), Université de Tunis El Manar (UTM)-Université de Tunis El Manar (UTM), Coordination Régionale de la lutte contre le Virus de L'Immunodéficience Humaine (COREVIH)-Centre Hospitalier Andrée Rosemon [Cayenne, Guyane Française]-Université des Antilles (UA), Centre d'investigation clinique Antilles-Guyane (CIC - Antilles Guyane), Institut National de la Santé et de la Recherche Médicale (INSERM)-CHU de la Martinique [Fort de France]-CHU Pointe-à-Pitre/Abymes [Guadeloupe] -Centre Hospitalier Andrée Rosemon [Cayenne, Guyane Française], and Coordination Régionale de la lutte contre le Virus de L'Immunodéficience Humaine (COREVIH Guyane)
- Subjects
0301 basic medicine ,Male ,Acinetobacter baumannii ,Imipenem ,MESH : Retrospective Studies ,Epidemiology ,MESH : Multilocus Sequence Typing ,MESH: beta-Lactamases ,MESH : Carbapenems ,Disease Outbreaks ,MESH: Carbapenems ,Disk Diffusion Antimicrobial Tests ,[ SDV.MP ] Life Sciences [q-bio]/Microbiology and Parasitology ,polycyclic compounds ,MESH : Bacterial Proteins ,Pharmacology (medical) ,MESH : Female ,MESH: Disease Outbreaks ,MESH: Bacterial Proteins ,Cross Infection ,Molecular Epidemiology ,MESH: Middle Aged ,biology ,MESH : beta-Lactamases ,General Medicine ,Middle Aged ,MESH : Adult ,MESH: Hospitals ,Hospitals ,3. Good health ,Electrophoresis, Gel, Pulsed-Field ,French Guiana ,MESH : Hospitals ,Infectious Diseases ,MESH: Multilocus Sequence Typing ,MESH: Electrophoresis, Gel, Pulsed-Field ,[SDV.MP]Life Sciences [q-bio]/Microbiology and Parasitology ,Amikacin ,MESH: Young Adult ,MESH: Disk Diffusion Antimicrobial Tests ,Female ,MESH: Acinetobacter Infections ,MESH : Cross Infection ,medicine.drug ,Acinetobacter Infections ,Microbiology (medical) ,Adult ,MESH : French Guiana ,MESH : Male ,030106 microbiology ,MESH : Molecular Epidemiology ,MESH : Young Adult ,Tazobactam ,beta-Lactam Resistance ,beta-Lactamases ,Microbiology ,Carbapenem-resistant ,03 medical and health sciences ,Young Adult ,Bacterial Proteins ,MESH : beta-Lactam Resistance ,MESH: French Guiana ,medicine ,Humans ,MESH: Molecular Epidemiology ,MESH : Acinetobacter Infections ,Intensive care unit ,MESH : Middle Aged ,MESH : Disease Outbreaks ,MESH : Disk Diffusion Antimicrobial Tests ,MESH : Acinetobacter baumannii ,Retrospective Studies ,MESH : Electrophoresis, Gel, Pulsed-Field ,MESH: Humans ,Molecular epidemiology ,business.industry ,MESH: Acinetobacter baumannii ,MESH : Humans ,Outbreak ,MESH: Cross Infection ,MESH: Retrospective Studies ,MESH: Adult ,biochemical phenomena, metabolism, and nutrition ,biology.organism_classification ,bacterial infections and mycoses ,MESH: Male ,MESH: beta-Lactam Resistance ,Carbapenems ,Colistin ,Nosocomial ,business ,MESH: Female ,Piperacillin ,Multilocus Sequence Typing - Abstract
International audience; This study investigated the clinical epidemiology and resistance mechanisms of Acinetobacter baumannii and characterised the clonal diversity of carbapenem-resistant A. baumannii (CRAB) during an ICU-associated outbreak at Cayenne Hospital, French Guiana. All non-duplicate A. baumannii isolates from 2008 to 2014 were tested for antibiotic susceptibility by disk diffusion. Multilocus sequence typing, pulsed-field gel electrophoresis (PFGE) and characterisation of carbapenemase-encoding genes were performed on CRAB. Of the 441 A. baumannii isolates, most were from males (54.0%) and were detected mainly from the ICU (30.8%) and medicine wards (21.8%). In the ICU, strains were mainly isolated from the respiratory tract (44.1%) and bloodstream (14.0%), whereas in medicine wards they mainly were from wound/drainage (36.5%) and bloodstream (25.0%). A. baumannii showed the greatest susceptibility to piperacillin/tazobactam (92.7%), imipenem (92.5%), colistin (95.6%) and amikacin (97.2%), being lower in the ICU and medicine wards compared with other wards. An outbreak of OXA-23-producing CRAB occurred in the 13-bed ICU in 2010. CRAB strains were more co-resistant to other antimicrobials compared with non-CRAB. Molecular genetics analysis revealed five sequence types [ST78, ST107 and ST642 and two new STs (ST830 and ST831)]. Analysis of PFGE profiles indicated cross-transmissions of CRAB within the ICU, between the ICU and one medicine ward during transfer of patients, and within that medicine ward. This study provides the first clinical and molecular data of A. baumannii from French Guiana and the Amazon basin. The ICU was the highest risk unit of this nosocomial outbreak of OXA-23-producing CRAB, which could subsequently disseminate within the hospital.
- Published
- 2016
21. Q Fever Pneumonia in French Guiana: Prevalence, Risk Factors, and Prognostic Score
- Author
-
Anne-Sophie Drogoul, Cédric B Chesnais, Aba Mahamat, Félix Djossou, Didier Raoult, Charlotte Boullé, Loïc Epelboin, Unité des Maladies Infectieuses et Tropicales (UMIT), Centre Hospitalier Andrée Rosemon [Cayenne, Guyane Française], Université de Guyane (UG), Recherches Translationnelles sur le VIH et les maladies infectieuses endémiques er émergentes (TransVIHMI), Université Cheikh Anta Diop [Dakar, Sénégal] (UCAD)-Institut de Recherche pour le Développement (IRD)-Université de Yaoundé I-Institut National de la Santé et de la Recherche Médicale (INSERM)-Université de Montpellier (UM)-Université Montpellier 1 (UM1), Institut Pasteur de la Guyane, Réseau International des Instituts Pasteur (RIIP), Unité de Recherche sur les Maladies Infectieuses et Tropicales Emergentes (URMITE), Institut de Recherche pour le Développement (IRD)-Aix Marseille Université (AMU)-Institut National de la Santé et de la Recherche Médicale (INSERM)-IFR48, INSB-INSB-Centre National de la Recherche Scientifique (CNRS), Service de médecine interne et maladies tropicales, CHU Bordeaux [Bordeaux]-Groupe hospitalier Saint-André, Équipe opérationnelle d’hygiène hospitalière, Recherches Translationnelles sur le VIH et les maladies infectieuses endémiques et émergentes (TransVIHMI), Université Montpellier 1 (UM1)-Institut de Recherche pour le Développement (IRD)-Université de Yaoundé I-Université Cheikh Anta Diop [Dakar, Sénégal] (UCAD)-Institut National de la Santé et de la Recherche Médicale (INSERM), and Institut des sciences biologiques (INSB-CNRS)-Institut des sciences biologiques (INSB-CNRS)-Centre National de la Recherche Scientifique (CNRS)
- Subjects
Male ,[SDV]Life Sciences [q-bio] ,0302 clinical medicine ,Risk Factors ,[SDV.MHEP.MI]Life Sciences [q-bio]/Human health and pathology/Infectious diseases ,Prevalence ,Cluster Analysis ,030212 general & internal medicine ,Aged, 80 and over ,biology ,Middle Aged ,Prognosis ,French Guiana ,3. Good health ,Community-Acquired Infections ,Infectious Diseases ,Predictive value of tests ,Female ,Q Fever ,medicine.drug ,Adult ,MESH: Pneumonia, Bacterial/epidemiology ,Microbiology (medical) ,medicine.medical_specialty ,Adolescent ,030231 tropical medicine ,Q fever ,03 medical and health sciences ,Predictive Value of Tests ,Internal medicine ,Pneumonia, Bacterial ,medicine ,Humans ,Risk factor ,Intensive care medicine ,Aged ,Retrospective Studies ,business.industry ,Retrospective cohort study ,Amoxicillin ,MESH: Community-Acquired Infections/epidemiology ,medicine.disease ,Coxiella burnetii ,biology.organism_classification ,Confidence interval ,respiratory tract diseases ,Pneumonia ,Logistic Models ,Multivariate Analysis ,MESH: Q Fever/epidemiology ,business ,[SDV.MHEP]Life Sciences [q-bio]/Human health and pathology - Abstract
Background Community-acquired pneumonia (CAP) is the major manifestation of Q fever, an emerging disease in French Guiana. Consequently, the empirical antibiotherapy used for the treatment of CAP combines doxycycline and the recommended amoxicillin. Our objectives were to estimate the prevalence of Q fever pneumonia and to build a prediction rule to identify patients with Q fever pneumonia for empirical antibiotic guidance. Methods A retrospective case-control study was conducted on inpatients admitted with CAP in the Department of Infectious Diseases of Cayenne Hospital from 2004 to 2007. Serodiagnosis for Coxiella burnetii was performed for all patients. Risk factor analysis was performed using multivariate logistic regression, and a prognostic score was computed using bootstrap procedures. The score performance characteristics were used to choose the best prediction rule to identify patients with Q fever pneumonia. Results One hundred thirty-one patients with CAP were included and the Q fever pneumonia prevalence was 24.4% (95% confidence interval [CI], 17.1-31.9). In multivariate analysis, male sex, middle age (age, 30-60 years), headache, leukocyte count 185 mg/L were independently associated with Q fever pneumonia. Patients with a predictive score ≤3 had a low risk of Q fever pneumonia with a negative predictive value of 0.97 (95% CI, .90-1) and a sensitivity of 0.97 (95% CI, .89-1). Conclusions The prediction rule described here accurately identifies patients with low risk of Q fever pneumonia and may help physicians to make more rational decisions about the empirical use of antibiotherapy. Further prospective studies should be performed to validate this score.
- Published
- 2012
- Full Text
- View/download PDF
22. Facteurs prédictifs de non-conformité d’antibioprophylaxie chirurgicale au cours d’un audit clinique prospectif
- Author
-
Pierre Couppié, M. Marie, Félix Djossou, A.-M. Simon, Aba Mahamat, A.-C. Dzierzek, and N. Blaise
- Subjects
Gynecology ,medicine.medical_specialty ,Anesthesiology and Pain Medicine ,Guideline adherence ,Practice patterns ,business.industry ,Medical audit ,medicine ,General Medicine ,business - Abstract
Resume Objectifs Evalue lors d’un audit prospectif, la compliance aux recommandations des pratiques d’antibioprophylaxie (ATBP) chirurgicale et identifier les facteurs predictifs de non-conformite. Patients et methode Etude prospective entre le 1 er fevrier et le 30 avril 2008 des conformites de l’indication (recommandee et prescrite ou non recommandee et non prescrite), de l’administration (molecule, dose, horaire et duree) ainsi que la conformite globale (indication et administration) des ATBP pour l’ensemble des patients admis pour une chirurgie propre ou propre-contaminee. Les facteurs predictifs de non-conformite globale ont ete estimes a partir d’analyse de regression logistique multivariee. Resultats Au total, 481 pratiques ont ete evaluees. La conformite de l’indication a ete de 83 %, celle de l’administration a ete de 56 %. La conformite globale n’a ete que de 37 %. Apres analyse multivariee, la prescription par un chirurgien (RR = 3,4, IC 95 % : 1,6–7,5), la chirurgie propre-contaminee (2,2 ; 1,4–3,7), la chirurgie traumatologique (1,87 ; 1,1–3,3), la chirurgie digestive (3,7 ; 1,8-7,5) et la chirurgie de la tete et du cou (11,4 ; 2,3–56,3) etaient predicteurs de non-conformite globale. Conclusion Cet audit a confirme la variabilite de la conformite aux pratiques d’ATBP selon le type de chirurgie et la classe de contamination. Plus pedagogique, il a estime, un risque plus eleve de non-respect du protocole en cas de prescription par les chirurgiens. Des plans d’actions specifiques ont ete mis en œuvre suite a la restitution des resultats a l’ensemble des acteurs concernes.
- Published
- 2012
- Full Text
- View/download PDF
23. Comparison of 3 Intensities of Stimulation Threshold for Brachial Plexus Blocks at the Midhumeral Level
- Author
-
Nathalie Vialles, Joël L’Hermite, Christophe Boisson, Nicolas Dion, Jean Emmanuel de La Coussaye, Philippe Cuvillon, Emmanuel Nouvellon, Michel Deleuze, Jacques Ripart, and Aba Mahamat
- Subjects
Adult ,Male ,Pain Threshold ,Time Factors ,Stimulation ,law.invention ,Young Adult ,Double-Blind Method ,Randomized controlled trial ,law ,Humans ,Medicine ,Brachial Plexus ,Local anesthesia ,Prospective Studies ,Radial nerve ,Aged ,Aged, 80 and over ,business.industry ,Ropivacaine ,Nerve Block ,General Medicine ,Middle Aged ,Hand ,Electric Stimulation ,Median nerve ,Intensity (physics) ,Anesthesiology and Pain Medicine ,Anesthesia ,Female ,business ,Brachial plexus ,medicine.drug - Abstract
We conducted this prospective randomized study to compare the success rate and the onset time between 3 intensities of stimulation threshold (0.5, 0.5-0.64, and 0.65-0.8 mA) when using a peripheral nerve stimulation at the midhumeral level.Sixty-nine adult patients undergoing elective hand surgery were studied. Blocks were performed using conventional nerve stimulation technique. Needle advance began at 2 mA (1 Hz, 0.1 millisecond). When motor response (MR) occurred at less than 0.5 mA, needle position was fixed for "group0.5 mA." For "group 0.5-0.64 mA," the needle was withdrawn until MR occurred at greater than 0.5 mA and disappeared at less than 0.5 mA. For "group0.65 mA," the needle was withdrawn until MR occurred at greater than 0.65 mA and disappeared at less than 0.65 mA. For each group, patients received 8 mL of ropivacaine 7.5 mg/mL on the 4 nerves (radial, median, ulnar, and musculocutaneous). Primary end point was the number of failed radial nerve sensory blocks at 30 mins.The time to perform the block was not different between the 3 groups (17 mins [SD, 7 mins] vs 13 mins [SD, 8 mins] and 13 mins [SD, 4 mins], respectively). The time required to obtain a complete sensory block was shorter for the 4 nerves in group0.5 mA, with a statistical significance for radial and musculocutaneous nerves in group0.5 mA versus group 0.5-0.64 mA and group0.65 mA. Patients in group0.5 mA had a greater success rate for complete sensory radial nerve compared with those of group 0.5-0.64 mA and group0.65 mA at any interval times between 5 and 30 mins (P = 0.0001). Supplemental local anesthesia was provided for the 3 groups more frequently for the median nerve, with no difference between groups. Group0.65 mA required 5 general anesthesias (20%) as compared with 1 (4%) in group0.5 mA (P0.05). No adverse event (dysesthesia) occurred after 48 hrs and 45 days.We conclude that intensity of stimulation influenced onset time and success rate.
- Published
- 2009
- Full Text
- View/download PDF
24. Could B-type Natriuretic Peptide (BNP) plasma concentration be useful to predict fluid in critically ill patients with acute circulatory failure?
- Author
-
Guillaume Louart, Aba Mahamat, Laurent Muller, Anne Polge, J. Ripart, J.-L. Teboul, Jean Yves Lefrant, J.-E. de La Coussaye, and J. P. Bertinchant
- Subjects
Resuscitation ,Receiver operating characteristic ,medicine.drug_class ,Critically ill ,business.industry ,Central venous pressure ,General Medicine ,Brain natriuretic peptide ,Preload ,Anesthesiology and Pain Medicine ,Anesthesia ,cardiovascular system ,Natriuretic peptide ,medicine ,cardiovascular diseases ,Acute circulatory failure ,business - Abstract
Background and objectives As B-type Natriuretic Peptide (BNP) is a marker of ventricular wall stress, the present study was aimed at determining whether plasma BNP concentration could predict fluid responsiveness in critically ill patients with acute circulatory failure. Methods This prospective and non randomized interventional study included 33 sedated, mechanically ventilated patients, with acute circulatory failure requiring cardiac output measurement and fluid challenge. Plasma BNP concentration was measured before and after fluid challenge (250 to 500 ml with infusion rate = 999 ml/h). An increase in stroke index (SI) greater than or equal to 15% allowed separation of responders from nonresponders. Receiver operating characteristic (ROC) curves were generated for BNP and compared to that of central venous pressure (CVP) that is routinely considered as a marker of cardiac preload. Results Among 33 patients, there were 24 responders. At baseline, BNP plasma values were less in responders (328 [35–1190] pg/ml versus 535 [223–5000] pg/ml, p Conclusion In critically ill patients with acute circulatory failure, BNP does not accurately predict fluid responsiveness.
- Published
- 2009
- Full Text
- View/download PDF
25. A Comparison of the Pharmacodynamics and Pharmacokinetics of Bupivacaine, Ropivacaine (with Epinephrine) and Their Equal Volume Mixtures with Lidocaine Used for Femoral and Sciatic Nerve Blocks: A Double-Blind Randomized Study
- Author
-
Jean Emmanuel de La Coussaye, Nathalie Vialles, Christophe Boisson, Jean-Christophe Boyer, Aba Mahamat, Philippe Cuvillon, Joël L’Hermite, Jacques Ripart, Laurence Dehour, Jean Yves Lefrant, and Emmanuel Nouvellon
- Subjects
Adult ,Male ,medicine.medical_specialty ,Epinephrine ,Lidocaine ,Endpoint Determination ,medicine.drug_class ,medicine.medical_treatment ,Double-Blind Method ,Pharmacokinetics ,Femoral nerve ,medicine ,Humans ,Vasoconstrictor Agents ,Ropivacaine ,Prospective Studies ,Anesthetics, Local ,Aged ,Pain Measurement ,Bupivacaine ,Leg ,Local anesthetic ,business.industry ,Nerve Block ,Middle Aged ,Amides ,Sciatic Nerve ,Surgery ,Anesthesiology and Pain Medicine ,Pharmacodynamics ,Anesthesia ,Nerve block ,Female ,business ,Femoral Nerve ,medicine.drug - Abstract
Mixtures of lidocaine with a long-acting local anesthetic are commonly used for peripheral nerve block. Few data are available regarding the safety, efficacy, or pharmacokinetics of mixtures of local anesthetics. In the current study, we compared the effects of bupivacaine 0.5% or ropivacaine 0.75% alone or in a mixed solution of equal volumes of bupivacaine 0.5% and lidocaine 2% or ropivacaine 0.75% and lidocaine 2% for surgery after femoral-sciatic peripheral nerve block. The primary end point was onset time.In a double-blind, randomized study, 82 adults scheduled for lower limb surgery received a sciatic (20 mL) and femoral (20 mL) peripheral nerve block with 0.5% bupivacaine (200 mg), a mixture of 0.5% bupivacaine 20 mL (100 mg) with 2% lidocaine (400 mg), 0.75% ropivacaine (300 mg) or a mixture of 0.75% ropivacaine 20 mL (150 mg) with 2% lidocaine (400 mg). Each solution contained epinephrine 1:200,000. Times to perform blocks, onset times (end of injection to complete sensory and motor block), duration of sensory and motor block, and morphine consumption via IV patient-controlled analgesia were compared. Venous blood samples of 5 mL were collected for determination of drug concentration at 0, 5, 15, 30, 45, 60, and 90 min after placement of the block.Patient demographics and surgical times were similar for all four groups. Sciatic onset times (sensory and motor block) were reduced by combining lidocaine with the long-acting local anesthetic. The onset of bupivacaine-lidocaine was 16 +/- 9 min versus 28 +/- 12 min for bupivacaine alone. The onset of ropivacaine-lidocaine was 16 +/- 12 min versus 23 +/- 12 for ropivacaine alone. Sensory blocks were complete for all patients within 40 min for those receiving bupivacaine-lidocaine versus 60 min for those receiving bupivacaine alone and 30 min for those receiving ropivacaine-lidocaine versus 40 min for those receiving ropivacaine alone (P0.05). Duration of sensory and motor block was significantly shorter in mixture groups. There was no difference among groups for visual analog scale pain scores and morphine consumption during the 48 h postoperative period, except for bupivacaine alone (median: 9 mg) versus bupivacaine-lidocaine mixture (15 mg), P0.01. There was no difference in the incidence of adverse events among groups. Plasma concentrations of bupivacaine and ropivacaine were higher, and remained elevated longer, in patients who received only the long-acting local anesthetic compared to patients who received the mixture of long-acting local anesthetic with lidocaine (P0.01).Mixtures of long-acting local anesthetics with lidocaine induced faster onset blocks of decreased duration. Whether there is a safety benefit is unclear, as the benefit of a decreased concentration of long-acting local anesthetic may be offset by the presence of a significant plasma concentration of lidocaine.
- Published
- 2009
- Full Text
- View/download PDF
26. Long-Term Monitoring of Visceral Leishmaniasis in Patients With AIDS
- Author
-
Patrick Bastien, Laurence Lachaud, Nathalie Bourgeois, Jacques Reynes, Isabelle Rouanet, and Aba Mahamat
- Subjects
First episode ,Acquired Immunodeficiency Syndrome ,medicine.medical_specialty ,business.industry ,Leishmaniasis ,medicine.disease ,Polymerase Chain Reaction ,Cohort Studies ,Infectious Diseases ,Visceral leishmaniasis ,Recurrence ,Risk Factors ,Internal medicine ,Cohort ,Immunology ,medicine ,Humans ,Leishmaniasis, Visceral ,Pharmacology (medical) ,Viral disease ,Risk factor ,business ,Prospective cohort study ,Cohort study - Abstract
Molecular methods have become essential in the diagnosis of visceral leishmaniasis (VL) in patients who have AIDS. The present study aimed at (1) identifying relapse risk factors for VL and (2) assessing the value of long-range routine polymerase chain reaction (PCR) monitoring in such patients (3) with a view to proposing decision-making elements for discontinuing specific secondary prophylaxis. A cohort of 27 HIV-positive patients was prospectively followed up during a period of 5 months to 9 years (median = 51 months) after a first episode of VL. The clinical and biologic follow-up protocol included routine Leishmania detection using peripheral blood and a previously validated PCR method. Quantitative and qualitative variables were statistically analyzed. Sixteen patients relapsed for a total of 38 relapses. CD4 counts less than 100 cells/microL and absence of highly active antiretroviral therapy at primary diagnosis and CD4 counts less than 100 cells/microL during follow-up were the major predictive factors for relapse. No relapse occurred when CD4 counts were greater than 200 cells/microL. The Leishmania PCR assay was positive in all clinical relapses and its negative predictive value was 100%. The PCR assay used here proved extremely useful for routine follow-up of VL in patients who had AIDS. Considering CD4 cell counts and Leishmania PCR assays these results allow defining proposals for discontinuing secondary prophylaxis and thus optimizing the clinical care of VL in these patients. (authors)
- Published
- 2008
- Full Text
- View/download PDF
27. Maintaining Antiretroviral Therapy Reduces the Risk of AIDS-Defining Events in Patients with Uncontrolled Viral Replication and Profound Immunodeficiency
- Author
-
Sophie Abgrall, Elina Teicher, Sophie Grabar, Dominique Costagliola, Aba Mahamat, Isabelle Kousignian, and Elisabeth Rouveix
- Subjects
Adult ,Male ,Microbiology (medical) ,Cart ,medicine.medical_specialty ,Virus Replication ,Cohort Studies ,Acquired immunodeficiency syndrome (AIDS) ,Risk Factors ,immune system diseases ,Internal medicine ,medicine ,Humans ,Prospective Studies ,Risk factor ,Sida ,Immunodeficiency ,Acquired Immunodeficiency Syndrome ,biology ,business.industry ,virus diseases ,Middle Aged ,Viral Load ,biology.organism_classification ,medicine.disease ,CD4 Lymphocyte Count ,Surgery ,Drug Combinations ,Regimen ,Infectious Diseases ,Anti-Retroviral Agents ,Disease Progression ,HIV-1 ,Female ,Viral disease ,business ,Viral load - Abstract
Background. The benefits of continuing antiretroviral therapy are questionable in human immunodeficiency virus (HIV) type 1-infected patients with profound immunodeficiency and multiple treatment failure due to viral resistance. Methods. From the French Hospital Database on HIV, we selected 12,765 patients with a CD4 + cell count
- Published
- 2008
- Full Text
- View/download PDF
28. Does short-term virologic failure translate to clinical events in antiretroviral-naive patients initiating antiretroviral therapy in clinical practice?
- Author
-
Adilia Warris, Julia Del amo, Roberto CAUDA, Renato Alberto Finazzi, Aba Mahamat, Antonio Chiesi, Giuseppe Ippolito, Dominique Costagliola, Margaret May, Vicente Soriano, Michael John Gill, Fiona Lampe, Maria Jose Amengual, Patrizio Pezzotti, Matthias Egger, Jonathan Sterne, Huldrych Günthard, STEFANO VELLA, Alexandra Montoliu, Willem Melchers, Adrian Streinu-Cercel, Sophie Matheron, Michael Kozal, André Cabié, Terese L Katzenstein, Annalisa Saracino, Cedric Arvieux, Bart Rijnders, Elisa De Lazzari, Alicja Wiercińska-Drapało, Carmen Cabellos, Felipe García, Mariana Gerschenson, University of Zurich, Mugavero, M J, Other departments, Amsterdam institute for Infection and Immunity, Amsterdam Public Health, Infectious diseases, General Internal Medicine, Graduate School, Global Health, Paediatric Infectious Diseases / Rheumatology / Immunology, Medical Microbiology and Infection Prevention, Antiretroviral Therapy Cohort, Collaboration, Mugavero, Mj, May, M, Harris, R, Saag, M, Costagliola, D, Egger, M, Phillips, A, Günthard, Hf, Dabis, F, Hogg, R, de Wolf, F, Fatkenheuer, G, Gill, Mj, Justice, A, D'Arminio Monforte, A, Lampe, F, Miró, Jm, Staszewski, S, Sterne, Ja, Piazza, Marcello, and Nappa, Salvatore
- Subjects
Male ,Infectious diseases and international health [NCEBP 13] ,Drug Resistance ,HIV Infections ,10234 Clinic for Infectious Diseases ,chemistry.chemical_compound ,0302 clinical medicine ,Abacavir ,virologic failure ,Odds Ratio ,Immunology and Allergy ,Drug Interactions ,030212 general & internal medicine ,Viral ,0303 health sciences ,Lamivudine ,virus diseases ,Lopinavir ,Middle Aged ,Viral Load ,3. Good health ,Pathogenesis and modulation of inflammation [N4i 1] ,Infectious Diseases ,Treatment Outcome ,Anti-Retroviral Agents ,naïve patients ,Combination ,2723 Immunology and Allergy ,RNA, Viral ,Reverse Transcriptase Inhibitors ,Drug Therapy, Combination ,Female ,Functional Neurogenomics [DCN 2] ,Infection and autoimmunity [NCMLS 1] ,medicine.drug ,Adult ,medicine.medical_specialty ,Efavirenz ,Nevirapine ,Adolescent ,Immunology ,610 Medicine & health ,Auto-immunity, transplantation and immunotherapy [N4i 4] ,Article ,Disease-Free Survival ,Invasive mycoses and compromised host [N4i 2] ,03 medical and health sciences ,Zidovudine ,Young Adult ,Drug Therapy ,Internal medicine ,Drug Resistance, Viral ,medicine ,Humans ,2403 Immunology ,030306 microbiology ,business.industry ,Poverty-related infectious diseases [N4i 3] ,2725 Infectious Diseases ,Nelfinavir ,chemistry ,10036 Medical Clinic ,HIV-1 ,RNA ,Ritonavir ,Microbial pathogenesis and host defense [UMCN 4.1] ,clinical event ,business ,Epidemiologic Methods ,HIV. antiretroviral therapy - Abstract
Contains fulltext : 70499.pdf (Publisher’s version ) (Closed access) OBJECTIVE: To determine whether differences in short-term virologic failure among commonly used antiretroviral therapy (ART) regimens translate to differences in clinical events in antiretroviral-naive patients initiating ART. DESIGN: Observational cohort study of patients initiating ART between January 2000 and December 2005. SETTING: The Antiretroviral Therapy Cohort Collaboration (ART-CC) is a collaboration of 15 HIV cohort studies from Canada, Europe, and the United States. STUDY PARTICIPANTS: A total of 13 546 antiretroviral-naive HIV-positive patients initiating ART with efavirenz, nevirapine, lopinavir/ritonavir, nelfinavir, or abacavir as third drugs in combination with a zidovudine and lamivudine nucleoside reverse transcriptase inhibitor backbone. MAIN OUTCOME MEASURES: Short-term (24-week) virologic failure (>500 copies/ml) and clinical events within 2 years of ART initiation (incident AIDS-defining event, death, and a composite measure of these two outcomes). RESULTS: Compared with efavirenz as initial third drug, short-term virologic failure was more common with all other third drugs evaluated; nevirapine (adjusted odds ratio = 1.87, 95% confidence interval (CI) = 1.58-2.22), lopinavir/ritonavir (1.32, 95% CI = 1.12-1.57), nelfinavir (3.20, 95% CI = 2.74-3.74), and abacavir (2.13, 95% CI = 1.82-2.50). However, the rate of clinical events within 2 years of ART initiation appeared higher only with nevirapine (adjusted hazard ratio for composite outcome measure 1.27, 95% CI = 1.04-1.56) and abacavir (1.22, 95% CI = 1.00-1.48). CONCLUSION: Among antiretroviral-naive patients initiating therapy, between-ART regimen, differences in short-term virologic failure do not necessarily translate to differences in clinical outcomes. Our results should be interpreted with caution because of the possibility of residual confounding by indication.
- Published
- 2008
29. Impact of infection control interventions and antibiotic use on hospital MRSA: a multivariate interrupted time-series analysis
- Author
-
Ian M. Gould, Jean-Pierre Daurès, Fiona M. MacKenzie, Dominique L. Monnet, Aba Mahamat, and K. Brooker
- Subjects
Microbiology (medical) ,Staphylococcus aureus ,medicine.medical_specialty ,Pediatrics ,Micrococcaceae ,medicine.drug_class ,media_common.quotation_subject ,Antibiotics ,Methicillin ,Hygiene ,Internal medicine ,Humans ,Medicine ,Infection control ,Pharmacology (medical) ,Medical prescription ,Antibacterial agent ,media_common ,Infection Control ,biology ,business.industry ,Outbreak ,General Medicine ,Staphylococcal Infections ,biochemical phenomena, metabolism, and nutrition ,bacterial infections and mycoses ,biology.organism_classification ,Quinolone ,Universal Precautions ,Drug Utilization ,Hospitals ,Anti-Bacterial Agents ,Infectious Diseases ,Scotland ,Multivariate Analysis ,Methicillin Resistance ,business ,Disinfectants ,Hand Disinfection - Abstract
Hospitals in the northeast of Scotland have experienced methicillin-resistant Staphylococcus aureus (MRSA) outbreaks since 1997. Several infection control measures were introduced sequentially to control MRSA, and antibiotic use has been monitored. From January 1997 to December 2004, data on the monthly percentage of non-duplicate MRSA infections (%MRSA) were collated from an intervention hospital (IH) and a control hospital (CH). Both hospitals introduced the use of alcohol hand gel in November 2002. Furthermore, the IH introduced an environmental MRSA swabbing programme in March 2001, chlorine disinfection of the environment in September 2001, discharge screening in December 2001, admission screening in November 2003 and environmental audits in March 2004. Multivariate dynamic regression analysis was used to evaluate the longitudinal effects of these interventions as measured by new clinical cases of MRSA. At the IH, the %MRSA increased between January 1998 and January 2001 and then decreased. At the CH, the %MRSA increased from January 1997 to December 2004. Introduction of alcohol hand gel was associated with an absolute decrease in %MRSA of 21% and 30%, respectively, for the IH and CH. At the IH, introduction of chlorine disinfection and environmental swabbing were, respectively, associated with a decrease in %MRSA of 27% immediately and 32% 3 months later. Discharge screening and environmental audit did not significantly affect %MRSA, whereas admission screening was associated with a 22% decrease in %MRSA 4 months later. Increasing macrolide use was associated with increasing %MRSA in both hospitals, and increasing quinolone use was associated with increasing %MRSA in the CH. Implementation of stepwise infection control measures was associated with a decrease in %MRSA in the IH. Introduction of an alcohol gel for hand hygiene was associated with a decrease in %MRSA in both hospitals. Antibiotic use also affects %MRSA, in particular that of macrolides and quinolones.
- Published
- 2007
- Full Text
- View/download PDF
30. Analgésie postopératoire par cathéter fémoral après fracture du col du fémur chez la personne âgée: étude prospective randomisée
- Author
-
J.J. Eledjam, J. Ripart, S Debureaux, Philippe Cuvillon, Eric Viel, P. Bruelle, Aba Mahamat, E Veyrat, and Christophe Boisson
- Subjects
Gynecology ,chemistry.chemical_compound ,medicine.medical_specialty ,Anesthesiology and Pain Medicine ,chemistry ,business.industry ,Fracture fixation ,medicine ,Femur ,General Medicine ,business ,Propacetamol ,Bolus injection - Abstract
Resume Introduction Le bloc tronculaire du nerf femoral a ete propose comme technique analgesique simple et efficace apres fracture du col du femur. Cette modalite d'analgesie administree en continue par catheter femoral (CF) est comparee a deux procedures d'analgesie classique : morphine sous-cutanee (s.c.) (M) et propacetamol intraveineuse (i.v.) (P). Methode Les patients (n = 62) operes sous anesthesie spinale etaient inclus et randomises en trois groupes en postoperatoire : groupe CF (catheter femoral : voie inguinale paravasculaire, injection d'un bolus initial et entretien par injection continue de ropivacaine 0,2 %), groupe P (propacetamol i.v. 2 g/6 heures), groupe M (Morphine s.c. : 0,05 mg/kg toutes les quatre heures). Une analgesie additionnelle etait standardisee : titration morphine intraveineuse puis relais par voie sous-cutanee par quatre heures. La consommation morphinique etait le critere principal de jugement. Les criteres secondaires etaient colliges : en effets adverses (morphine), morbidite, mortalite et score EVA. Resultats Les caracteristiques chirurgicales et anesthesiques etaient similaires pour les trois groupes. Apres titration morphinique, les scores EVA etaient similaires entre les groupes de 0 a 48 heures. La consommation totale de morphine etait plus elevee dans le groupe CF : 26 mg (5–42) versus P : 8 mg (3–12) (p = 0,0001) ou M : 19 mg (8–33) (p Conclusion L'analgesie par catheter femoral continu apres fracture du col du femur ne montre pas de reel benefice pour un cout financier significativement plus eleve.
- Published
- 2007
- Full Text
- View/download PDF
31. A multifaceted intervention designed to improve medical management of moderate to advanced chronic kidney disease in HIV-infected patients: a cluster randomised trial
- Author
-
P Brazille, Johan Chanal, N. de Castro, B. Lefebvre, Sophie Abgrall, N Petit, M Marcou, Pascal Pugliese, A Parrot, F Meier, Yazdan Yazdanpanah, A Signori-Schmuck, Hana Selinger-Leneman, Pierre Delobel, F Touam, A Cros, Claire Rouzaud, Philippe Bossi, J. P. Faller, Jean-Marc Mauboussin, Faiza Ajana, V Perronne, V Chambrin, Olivier Lortholary, Laurent Alric, V. Gendrin, C Sautron, K Benhadj, H Gil, C Lascoux, F Raffi, JE Kahn, Michel Vidal, J. J. Laurichesse, O Ruyer, F Brunel, Pascal Chavanet, J. Durant, J. M. Chapplain, T. Perpoint, D Blanc, S Casanova, Frédéric Méchaï, P Poubeau, M Benomar, David Zucman, P Fischer, H Fischer, V Ronat, D Coban, Elisabeth Rouveix, H. Berthé, E Roveix, Corinne Isnard-Bagnis, Aurélie Fillion, P Loulergue, Jennifer M. Rohan, Isabelle Ravaux, Catherine Michel, C Faudon, Jacques Gilquin, J. M. Livrozet, Christian Chidiac, G Wartel, Patricia Enel, G. Beck-Wirth, I Prade, O. Derradji, Jean-Paul Viard, Cécile Goujard, R Cohen Valensi, M Batard, Jean-Luc Meynard, G Camuset, Jacques Cadranel, Christian Pradier, S Gohier, Jean-François Bergmann, Francis Barin, D. Makhloufi, Philippe Gerhardt, A Canestri, Lionel Piroth, S Greffe, N Biezunski, C Bolliot, L Toko, G Mboungou, Jérôme Moreau, Valérie Potard, H Masson, Eric Rosenthal, Jacques Reynes, André Cabié, Gilles Pialoux, P Granet Brunello, F Durand, Véronique Obry-Roguet, Jade Ghosn, V Walter, P Gazalet, O Boulat, P M Girard, A Ménard, M. Môle, G Martin Blondel, M Hamidi, C Lupin, P Druart, Sophie Matheron, Catherine Chirouze, P. De Truchis, Laurent Cotte, P. Del Giudice, Caroline Dupont, Anne Frésard, C Jung, V Payssan, M Saidani, C. Chesnel, Véronique Joly, S Abgrall, B Wifaq, Bruno Hoen, I Fabre, E Pannier Metzger, M Beyrne, Christian Rabaud, C. Gaud, Pierre Durieux, S Makhloufi, Eric Billaud, Jean-Marc Lacombe, T Akpan, PY Dides, Dominique Mathez, V Delcey, P. Sellier, A Naqvi, Amanda Lopes, Laurent Hustache-Mathieu, C Bartoli, V Marcou, Murielle Mary-Krause, Elisabeth Botelho-Nevers, K Samar, Hervé Tissot-Dupont, M Ruquet, Laurence Weiss, Boue F, Philippe Morand, I Lamaury, L Meddeb, Nadia Valin, M Delestan, N. Jacquemet, N Méaux-Ruault, A Gergely, M. Blanc, M Sordage, L Sutton, Dominique Costagliola, V Thomas, PH Consigny, G Cessot, C Le Jeunne, A Freire Maresca, A Greder Belan, Jean-Pierre Morini, G Astier, D. Martin, Pierre-Marie Roger, E Bourzam, G Melica-Gregoire, Nicolas Vignier, B. Taverne, P. Leclercq, M. Sebire, A Adda, A Meybeck, MG Lebrette, André Boibieux, T. Allegre, Nicolas Dupin, M. Parrinello, S Roussin-Bretagne, Christine Jacomet, Laurence Gérard, Jean Deleuze, A S Ritleng, M Raho-Moussa, Marialuisa Partisani, Daniel Vittecoq, M André, Albert Sotto, Pierre Tattevin, S Marque Juillet, Antolini-Bouvenot, Sylvie Abel, M Guivarch, S Lang, P. Honoré, A Lavolé, C. Majerholc, Gilles Hittinger, Marguerite Guiguet, N Magy-Bertrand, Alain Lafeuillade, Elina Teicher, JM Riou, B Slama, Sophie Grabar, N. Viget, P Genet, Faouzi Souala, X. Duval, Lise Cuzin, B. Marchou, D Bonnabel, O. Faucher, S Stegmann, C Veyssier-Belot, I Perbost, K Bourdic, Cédric Arvieux, V Masse, L Pellissier, Giovanna Melica, S Lariven, S Chebrek, H Zerazhi, G Philip, Hugues Melliez, D Marigot-Outtandy, Mark Bloch, E Fourn, E. Billaud, J. Gerbe, C Dhiver, Benveniste O, Delphine Bonnet, D. Quinsat, V Daneluzzi, E Haustraete, P Guet, Dominique Salmon, Christophe Rioux, E Duvallon, E. Mortier, G Borgherini, P Goubin, D. Costagliola, Renaud Verdon, M J Soavi, A. Simon, F Zeng, Aba Mahamat, Mathieu Nacher, P Colardelle, F Granier, E Hope-Rapp, M. Poupard, V Vanticlke, M P Bouillon, C Clavel, Ml Lucas, P. Chiarello, Fabienne Caby, G Jacques, Juliette Pavie, MP Pietri, Blandine Denis, P. Miailhes, Sylvie Bregigeon, B Mouchet, Marie-Aude Khuong-Josses, P Thibaut, Antoine Rachas, H Laurichesse, Sylvie Dargere, C Godin Collet, Odile Launay, Jacques Gasnault, Clotilde Allavena, C. Dumont, Isabelle Poizot-Martin, M. Ratajczak, A. Maignan, A Brunon-Gagneux, Olivier Epaulard, A Therby, Tristan Ferry, E Reimann, Laurent Boyer, Régine Doncesco, Eric Cua, K Risso, Claudine Duvivier, Leila Adriouch, W. Rozenbaum, Christian Perronne, R Sambuc, I Kansau, J. F. Faucher, Florence Huber, J. M. Ruiz, Ma Khuong, Sandrine Pierre-François, Laurence Lievre, G Breton, J.-M. Molina, C. Tomei, M Guiguet, A Proust, L Fonquernie, D. Bornarel, David Rey, Isabelle Rouanet, C Guglielminotti, Jérôme Tourret, V. Reliquet, A Palacin, C Cheneau, Eric Oksenhendler, P Féret, B Montoya, V Lambry, N Hall, Jean-Daniel Lelièvre, Delphine Croisier, C Ricaud, M Ptak, Pierre Couppié, S Mokhtari, Y Welker, R Rodet, T May, Epidémiologie, stratégies thérapeutiques et virologie cliniques dans l'infection à VIH, Université Pierre et Marie Curie - Paris 6 (UPMC)-Institut National de la Santé et de la Recherche Médicale (INSERM), Ecologie et Evolution des Microorganismes (EEM), Université Paris 13 (UP13)-Université Paris Diderot - Paris 7 (UPD7)-Université Sorbonne Paris Cité (USPC)-Institut National de la Santé et de la Recherche Médicale (INSERM), Centre hospitalier universitaire de Nantes (CHU Nantes), Service des maladies infectieuses et réanimation médicale [Rennes] = Infectious Disease and Intensive Care [Rennes], CHU Pontchaillou [Rennes], Fonction, structure et inactivation d'ARN bactériens, Université de Rennes (UR)-Institut National de la Santé et de la Recherche Médicale (INSERM)-Structure Fédérative de Recherche en Biologie et Santé de Rennes ( Biosit : Biologie - Santé - Innovation Technologique ), Epidémiologie, Systèmes d'Information, Modélisation, Université Pierre et Marie Curie - Paris 6 (UPMC)-Assistance publique - Hôpitaux de Paris (AP-HP) (AP-HP)-Institut National de la Santé et de la Recherche Médicale (INSERM)-CHU Pitié-Salpêtrière [AP-HP], Assistance publique - Hôpitaux de Paris (AP-HP) (AP-HP)-Sorbonne Université (SU)-Sorbonne Université (SU), Centre de Recherche des Cordeliers (CRC (UMR_S 872)), Université Pierre et Marie Curie - Paris 6 (UPMC)-Université Paris Descartes - Paris 5 (UPD5)-Institut National de la Santé et de la Recherche Médicale (INSERM)-Centre National de la Recherche Scientifique (CNRS), Institut National de la Santé et de la Recherche Médicale (INSERM), ANRS, 2009, the French Ministry of Health, Université Pierre et Marie Curie - Paris 6 ( UPMC ) -Institut National de la Santé et de la Recherche Médicale ( INSERM ), Ecologie et Evolution des Microorganismes ( EEM ), Université Paris Diderot - Paris 7 ( UPD7 ) -Université Paris 13 ( UP13 ) -Université Sorbonne Paris Cité ( USPC ) -Institut National de la Santé et de la Recherche Médicale ( INSERM ), Centre hospitalier universitaire de Nantes ( CHU Nantes ), Service des maladies infectieuses et réanimation médicale, Université de Rennes 1 ( UR1 ), Université de Rennes ( UNIV-RENNES ) -Université de Rennes ( UNIV-RENNES ) -Hôpital Pontchaillou, Université de Rennes ( UNIV-RENNES ) -Université de Rennes ( UNIV-RENNES ) -Institut National de la Santé et de la Recherche Médicale ( INSERM ) -Structure Fédérative de Recherche en Biologie et Santé de Rennes ( Biosit : Biologie - Santé - Innovation Technologique ), Université Pierre et Marie Curie - Paris 6 ( UPMC ) -Assistance publique - Hôpitaux de Paris (AP-HP)-Institut National de la Santé et de la Recherche Médicale ( INSERM ) -CHU Pitié-Salpêtrière [APHP], Centre de Recherche des Cordeliers ( CRC (UMR_S 872) ), Université Pierre et Marie Curie - Paris 6 ( UPMC ) -Université Paris Descartes - Paris 5 ( UPD5 ) -Institut National de la Santé et de la Recherche Médicale ( INSERM ) -Centre National de la Recherche Scientifique ( CNRS ), Université Paris Diderot - Paris 7 (UPD7)-Université Paris 13 (UP13)-Université Sorbonne Paris Cité (USPC)-Institut National de la Santé et de la Recherche Médicale (INSERM), Université de Rennes 1 (UR1), Université de Rennes (UNIV-RENNES)-Université de Rennes (UNIV-RENNES)-Institut National de la Santé et de la Recherche Médicale (INSERM)-Structure Fédérative de Recherche en Biologie et Santé de Rennes ( Biosit : Biologie - Santé - Innovation Technologique ), Université Paris Descartes - Paris 5 (UPD5)-Université Pierre et Marie Curie - Paris 6 (UPMC)-Institut National de la Santé et de la Recherche Médicale (INSERM)-Centre National de la Recherche Scientifique (CNRS), Université de Rennes (UNIV-RENNES)-Université de Rennes (UNIV-RENNES)-Hôpital Pontchaillou, and Université Pierre et Marie Curie - Paris 6 (UPMC)-Assistance publique - Hôpitaux de Paris (AP-HP) (APHP)-Institut National de la Santé et de la Recherche Médicale (INSERM)-CHU Pitié-Salpêtrière [APHP]
- Subjects
Male ,Microbiology (medical) ,Nephrology ,medicine.medical_specialty ,HIV Infections ,urologic and male genital diseases ,law.invention ,Randomized controlled trial ,law ,[ SDV.MP ] Life Sciences [q-bio]/Microbiology and Parasitology ,Internal medicine ,Humans ,Medicine ,Cluster randomised controlled trial ,Aged ,business.industry ,Guideline ,Middle Aged ,medicine.disease ,HIV infection ,Confidence interval ,3. Good health ,clinical practice ,Clinical trial ,Treatment Outcome ,Infectious Diseases ,Blood pressure ,[SDV.MP]Life Sciences [q-bio]/Microbiology and Parasitology ,Practice Guidelines as Topic ,Physical therapy ,cluster randomized trial ,Kidney Failure, Chronic ,Female ,business ,chronic kidney disease ,Glomerular Filtration Rate ,Kidney disease - Abstract
International audience; Background - Chronic kidney disease (CKD) is frequent in individuals infected with human immunodeficiency virus (HIV). Progression to end-stage renal disease can be slowed by appropriate medical management. Methods - To assess whether active promotion of guidelines improves CKD management, we conducted a cluster randomized controlled trial within the French Hospital Database on HIV (FHDH-ANRS CO4). We randomized 46 centers participating in the FHDH to either simple information on guideline availability or active promotion with a multifaceted and repeated intervention comprising reminders and audit feedback and targeting of local opinion leaders carried out between April 2009 and April 2010. Outcome measure was CKD management adequacy assessed before and 2 years after the beginning of the intervention in HIV-infected patients with moderate to severe CKD. CKD management was considered adequate in case of referral to a nephrologist or if proteinuria, blood pressure, low-density lipoprotein cholesterol level, and glycemia had been measured during the previous year and medications had been prescribed when necessary. Results - Three hundred six patients were enrolled, of whom 238 (78%) completed the 2 years of follow-up. During the study period, the percentage of patients receiving adequate CKD management improved from 64.1% to 70.4% (+6.3%) in the active arm and from 68.3% to 75.6% (+7.3%) in the control arm (adjusted mean difference, -0.7 percentage points [95% confidence interval: -9.2 to 7.9]; P = .95). The biggest impact of active promotion was on the management of proteinuria and blood pressure. Conclusions - Adequate compliance with CKD management guidelines improved slightly between 2009 and 2011, with no difference between the simple information and active promotion arms. Clinical trials registration - CCTIRS 10.150 and CNIL DR-2010-379.
- Published
- 2015
- Full Text
- View/download PDF
32. Later cART Initiation in Migrant Men from Sub-Saharan Africa without Advanced HIV Disease in France
- Author
-
Laure-Amélie de Monteynard, Rosemary Dray-Spira, Pierre de Truchis, Sophie Grabar, Odile Launay, Jean-Luc Meynard, Marie-Aude Khuong-Josses, Jacques Gilquin, David Rey, Anne Simon, Juliette Pavie, Aba Mahamat, Sophie Matheron, Dominique Costagliola, Sophie Abgrall, French Hospital Database on HIV, Institut Pierre Louis d'Epidémiologie et de Santé Publique (iPLESP), Institut National de la Santé et de la Recherche Médicale (INSERM)-Université Pierre et Marie Curie - Paris 6 (UPMC), Département de Médecine Aiguë Spécialisée, Assistance publique - Hôpitaux de Paris (AP-HP) (AP-HP)-Hôpital Raymond Poincaré [AP-HP]-Université Paris Descartes - Paris 5 (UPD5), Université Paris Descartes - Paris 5 (UPD5), Unité de biostatistique et épidémiologie, Assistance publique - Hôpitaux de Paris (AP-HP) (AP-HP)-Hôpital Cochin [AP-HP], Assistance publique - Hôpitaux de Paris (AP-HP) (AP-HP), Hôpital Cochin [AP-HP], Services des Maladies Infectieuses et Tropicales [CHU Saint-Antoine], CHU Saint-Antoine [AP-HP], Assistance publique - Hôpitaux de Paris (AP-HP) (AP-HP)-Sorbonne Université (SU)-Assistance publique - Hôpitaux de Paris (AP-HP) (AP-HP)-Sorbonne Université (SU), Service des maladies infectieuses et tropicales, Hôpital Delafontaine, Unité d'immunoinfectiologie, Hôpital Hôtel-Dieu [Paris], Assistance publique - Hôpitaux de Paris (AP-HP) (AP-HP)-Assistance publique - Hôpitaux de Paris (AP-HP) (AP-HP), Centre de soins de l'infection par le VIH, Les Hôpitaux Universitaires de Strasbourg (HUS), CHU Pitié-Salpêtrière [AP-HP], Assistance publique - Hôpitaux de Paris (AP-HP) (AP-HP)-Sorbonne Université (SU), Service d'Immunologie Clinique, Hôpital Européen Georges Pompidou, Paris, Centre Hospitalier Andrée Rosemon [Cayenne, Guyane Française], Université Paris Diderot - Paris 7 (UPD7), Assistance publique - Hôpitaux de Paris (AP-HP) (AP-HP)-AP-HP - Hôpital Bichat - Claude Bernard [Paris], Assistance publique - Hôpitaux de Paris (AP-HP) (AP-HP)-Université Paris Diderot - Paris 7 (UPD7), Hôpital Avicenne [AP-HP], Université Pierre et Marie Curie - Paris 6 (UPMC)-Institut National de la Santé et de la Recherche Médicale (INSERM), HAL UPMC, Gestionnaire, Institut Pierre Louis d'Epidémiologie et de Santé Publique ( iPLESP ), Université Pierre et Marie Curie - Paris 6 ( UPMC ) -Institut National de la Santé et de la Recherche Médicale ( INSERM ), Assistance publique - Hôpitaux de Paris (AP-HP)-AP-HP Hôpital Raymond Poincaré [Garches]-Université Paris Descartes - Paris 5 ( UPD5 ), Université Paris Descartes - Paris 5 ( UPD5 ), Assistance publique - Hôpitaux de Paris (AP-HP)-CHU Cochin [AP-HP], CHU Cochin [AP-HP], Service des maladies infectieuses et tropicales [CHU Saint-Antoine], Assistance publique - Hôpitaux de Paris (AP-HP)-CHU Saint-Antoine [APHP], Département de médecine interne, CHU Pitié-Salpêtrière [APHP], Université Paris Diderot - Paris 7 ( UPD7 ), Assistance publique - Hôpitaux de Paris (AP-HP)-AP-HP - Hôpital Bichat - Claude Bernard [Paris]-Université Paris Diderot - Paris 7 ( UPD7 ), and AP-HP Groupe Hospitalier Avicenne
- Subjects
Cart ,Adult ,Male ,Adolescent ,Anti-HIV Agents ,lcsh:Medicine ,HIV Infections ,[ SDV.MP.VIR ] Life Sciences [q-bio]/Microbiology and Parasitology/Virology ,Men who have sex with men ,Time-to-Treatment ,Acquired immunodeficiency syndrome (AIDS) ,Antiretroviral Therapy, Highly Active ,Medicine ,Humans ,lcsh:Science ,Africa South of the Sahara ,[SDV.MP.VIR] Life Sciences [q-bio]/Microbiology and Parasitology/Virology ,Transients and Migrants ,Multidisciplinary ,business.industry ,Coinfection ,Hazard ratio ,lcsh:R ,virus diseases ,Hepatitis C ,Viral Load ,medicine.disease ,Hepatitis B ,CD4 Lymphocyte Count ,Immunology ,Cohort ,[SDV.MP.VIR]Life Sciences [q-bio]/Microbiology and Parasitology/Virology ,HIV-1 ,Patient Compliance ,lcsh:Q ,Female ,France ,business ,Viral load ,Demography ,Research Article - Abstract
International audience; ObjectiveTo compare the time from entry into care for HIV infection until combination antiretroviral therapy (cART) initiation between migrants and non migrants in France, excluding late access to care.MethodsAntiretroviral-naïve HIV-1-infected individuals newly enrolled in the FHDH cohort between 2002–2010, with CD4 cell counts >200/μL and no previous or current AIDS events were included. In three baseline CD4 cell count strata (200–349, 350-499, ≥500/μL), we examined the crude time until cART initiation within three years after enrolment according to geographic origin, and multivariable hazard ratios according to geographic origin, gender and HIV-transmission group, with adjustment for baseline age, enrolment period, region of care, plasma viral load, and HBV/HBC coinfection.ResultsAmong 13338 individuals, 9605 (72.1%) were French natives (FRA), 2873 (21.4%) were migrants from sub-Saharan Africa/non-French West Indies (SSA/NFW), and 860 (6.5%) were migrants from other countries. Kaplan-Meier probabilities of cART initiation were significantly lower in SSA/NFW than in FRA individuals throughout the study period, regardless of the baseline CD4 stratum. After adjustment, the likelihood of cART initiation was respectively 15% (95%CI, 1–28) and 20% (95%CI, 2–38) lower in SSA/NFW men than in FRA men who had sex with men (MSM) in the 350-499 and ≥500 CD4 strata, while no difference was observed between other migrant groups and FRA MSM.ConclusionSSA/NFW migrant men living in France with CD4 >350/μL at entry into care are more likely to begin cART later than FRA MSM, despite free access to treatment. Administrative delays in obtaining healthcare coverage do not appear to be responsible.
- Published
- 2015
- Full Text
- View/download PDF
33. Boosted Lopinavir- Versus Boosted Atazanavir-Containing Regimens and Immunologic, Virologic, and Clinical Outcomes: A Prospective Study of HIV-Infected Individuals in High-Income Countries
- Author
-
Isabel Hurtado, Santiago Pérez-Hoyos, Consuelo Viladés, Adilia Warris, Federico Pulido, Eva Calabuig, Oscar Murillo Rubio, Dimitrios Paraskevis, Julia Del amo, Pablo Barreiro, INMA JARRIN, Arantza Sanvisens, Enrique Bernal Morell, Roberto Muga, Mariona Xercavins, Jean-Francois Bergmann, Aba Mahamat, Ignacio Pérez Valero, DAVID DALMAU, Clifford Leen, Dominique Costagliola, Jim Young, Vicente Soriano, Montserrat Vargas Laguna, Marcela Guevara, Soraya Boucherit, Jesus Castilla, Jean-Marie Michot, José A. Oteo, Maria Jose Amengual, Vicente Boix, Jonathan Sterne, Valerie Delpech, Jane Anderson, Alexandra Montoliu, Esperanza Merino de Lucas, Sophie Matheron, Michael Kozal, Caroline Sabin, André Cabié, Susana Monge, Luis Fernando Lopez.Cortes, Sylvie ABEL, Cedric Arvieux, Félix Gutiérrez, Bart Rijnders, Eulalia Valle-Garay, Juan Berenguer, Carmen Cabellos, Amy Justice, Felipe García, Joaquín Portilla, Mariana Gerschenson, Amsterdam institute for Infection and Immunity, Amsterdam Public Health, Global Health, Graduate School, Other departments, Infectious diseases, Paediatric Infectious Diseases / Rheumatology / Immunology, General Internal Medicine, Center of Experimental and Molecular Medicine, Dermatology, Medical Microbiology and Infection Prevention, Centre Hospitalier Universitaire de Nîmes (CHU Nîmes), Medische Microbiologie, RS: CAPHRI School for Public Health and Primary Care, RS: CAPHRI - R4 - Health Inequities and Societal Participation, and Interne Geneeskunde
- Subjects
Male ,lnfectious Diseases and Global Health Radboud Institute for Molecular Life Sciences [Radboudumc 4] ,HIV Infections ,Cohort Studies ,chemistry.chemical_compound ,[SDV.MHEP.MI]Life Sciences [q-bio]/Human health and pathology/Infectious diseases ,immune system diseases ,Antiretroviral Therapy, Highly Active ,Medicine ,Prospective Studies ,Cooperative Behavior ,Prospective cohort study ,atazanavir ,Hazard ratio ,virus diseases ,Lopinavir ,Middle Aged ,Viral Load ,Europe ,Treatment Outcome ,Infectious Diseases ,[SDV.MP]Life Sciences [q-bio]/Microbiology and Parasitology ,HIV/AIDS ,[SDV.IMM]Life Sciences [q-bio]/Immunology ,Female ,Viral load ,medicine.drug ,Adult ,Microbiology (medical) ,medicine.medical_specialty ,Efavirenz ,Adolescent ,Anti-HIV Agents ,Atazanavir Sulfate ,Young Adult ,Internal medicine ,Humans ,observational studies ,business.industry ,Developed Countries ,HIV ,mortality ,United States ,CD4 Lymphocyte Count ,Atazanavir ,lopinavir ,Regimen ,chemistry ,Immunology ,business - Abstract
Current clinical guidelines consider regimens consisting of either ritonavir-boosted atazanavir or ritonavir-boosted lopinavir and a nucleoside reverse transcriptase inhibitor (NRTI) backbone among their recommended and alternative first-line antiretroviral regimens. However, these guidelines are based on limited evidence from randomized clinical trials and clinical experience.We compared these regimens with respect to clinical, immunologic, and virologic outcomes using data from prospective studies of human immunodeficiency virus (HIV)-infected individuals in Europe and the United States in the HIV-CAUSAL Collaboration, 2004-2013. Antiretroviral therapy-naive and AIDS-free individuals were followed from the time they started a lopinavir or an atazanavir regimen. We estimated the 'intention-to-treat' effect for atazanavir vs lopinavir regimens on each of the outcomes.A total of 6668 individuals started a lopinavir regimen (213 deaths, 457 AIDS-defining illnesses or deaths), and 4301 individuals started an atazanavir regimen (83 deaths, 157 AIDS-defining illnesses or deaths). The adjusted intention-to-treat hazard ratios for atazanavir vs lopinavir regimens were 0.70 (95% confidence interval [CI], .53-.91) for death, 0.67 (95% CI, .55-.82) for AIDS-defining illness or death, and 0.91 (95% CI, .84-.99) for virologic failure at 12 months. The mean 12-month increase in CD4 count was 8.15 (95% CI, -.13 to 16.43) cells/?L higher in the atazanavir group. Estimates differed by NRTI backbone.Our estimates are consistent with a lower mortality, a lower incidence of AIDS-defining illness, a greater 12-month increase in CD4 cell count, and a smaller risk of virologic failure at 12 months for atazanavir compared with lopinavir regimens.? The Author 2015. Published by Oxford University Press on behalf of the Infectious Diseases Society of America. All rights reserved. For Permissions, please e-mail: journals.permissions@oup.com.
- Published
- 2015
- Full Text
- View/download PDF
34. Profils de résistance des souches urinaires de Proteus mirabilis de 1999 à 2005 au CHU de Nîmes
- Author
-
N. Bouziges, J.-P. Lavigne, Aba Mahamat, Jean-Pierre Daurès, and Albert Sotto
- Subjects
Gynecology ,medicine.medical_specialty ,business.industry ,Medicine ,General Medicine ,business - Abstract
Resume But de l'etude Analyser l'evolution de la resistance des souches urinaires de Proteus mirabilis du 1er janvier 1999 au 31 decembre 2005 au CHU de Nimes. Patients et methodes Nous avons collige retrospectivement les souches non redondantes issues des infections et colonisations urinaires de l'ensemble des services sauf des urgences. Resultats Parmi 1008 souches, 63,1 % ont ete isolees chez les femmes et la moyenne d'âge etait de 76 ans. Le taux moyen de resistance etait de 59,0 % pour l'amoxicilline (AMX), 48,0 % pour la piperacilline (PIP), 3,9 % pour le cefotaxime, 33,9 % pour l'amoxicilline + acide clavulanique (AMC) et 2,8 % pour l'association piperacilline + tazobactam (TZP). Une augmentation significative de la resistance a ete notee pour AMC et TZP. Ce taux moyen de resistance etait de 35,0 % pour la norfloxacine, 34,8 % pour ofloxacine et 23,5 % pour la ciprofloxacine. Aucune augmentation de la resistance aux fluoroquinolones (FQ) n'a ete constatee a l'exception de la ciprofloxacine tandis qu'une hausse significative a ete notee pour les aminosides. Une tendance a la baisse de la resistance au cotrimoxazole a ete constatee avec un taux de 33,2 %. Conclusion L'augmentation de la resistance pour AMC et TZP pourrait s'expliquer par l'emergence des β-lactamases particulierement a spectre etendu (10 %). La resistance aux FQ est preoccupante. En revanche, P. mirabilis reste sensible aux cephalosporines de troisieme generation ainsi qu'a TZP malgre la tendance significative a l'augmentation de resistance. L'amikacine est l'aminoside le plus efficace. Ces donnees pronent pour un maintien de la surveillance afin d'optimiser l'usage des antibiotiques.
- Published
- 2006
- Full Text
- View/download PDF
35. Differential Impact of Combination Antiretroviral Therapy in Preventing Kaposi's Sarcoma With and Without Visceral Involvement
- Author
-
Aba Mahamat, Sophie Grabar, Dominique Costagliola, Eric Rosenthal, Pascal Del Giudice, and Bruno Abraham
- Subjects
Adult ,Male ,Cart ,Cancer Research ,medicine.medical_specialty ,HIV Infections ,Antiviral Agents ,Risk Assessment ,Medical Records ,Pharmacotherapy ,Acquired immunodeficiency syndrome (AIDS) ,Risk Factors ,Antiretroviral Therapy, Highly Active ,Internal medicine ,medicine ,Humans ,Sarcoma, Kaposi ,Kaposi's sarcoma ,Proportional Hazards Models ,Retrospective Studies ,business.industry ,Proportional hazards model ,Incidence (epidemiology) ,virus diseases ,Retrospective cohort study ,medicine.disease ,Surgery ,Regimen ,Treatment Outcome ,Oncology ,Drug Therapy, Combination ,Female ,France ,business - Abstract
Purpose To study the impact of different potent combined antiretroviral treatment (cART) on the incidence of HIV-associated Kaposi's sarcoma (KS) with and without visceral involvement. Patients and Methods Patients were selected from the French Hospital Database on HIV, a large hospital cohort. The risk of KS was estimated by using Cox proportional hazards models adjusting for age, the CD4 cell nadir, the HIV exposure category, prior AIDS, cART, and the type of cART regimen. cART regimens were distinguished according to whether they contained protease inhibitor (PI), non-nucleoside analog (NNRTI), both, or only nucleoside analog (NRTI). Separate analyzes were conducted according to the initial visceral involvement of KS. Results Among the 54,999 patients included in this study (182,756 person-years of follow-up), 1,634 patients were diagnosed with KS during follow-up, of whom 421 had visceral involvement at diagnosis. The KS incidence rate fell from 32 per 1,000 person-years in 1993 to 1994 to 3 per 1,000 person-years after 1999. PI-containing and NNRTI-containing cART regimens were associated with similar reductions in the risk of KS (hazard ratio, 0.68; 95%CI, 0.61 to 0.75; HR, 0.62; 95% CI, 0.54 to 0.71, respectively). The risk of visceral KS fell more strongly than the risk of cutaneous KS (> 50% and < 30%, respectively). Conclusion The incidence of KS, and especially visceral KS, has fallen sharply since the advent of cART. This effect is likely due to immune restoration rather than to a specific effect on the tumoral process, as PI-containing and NNRTI-containing regimens had similar preventive efficacy.
- Published
- 2006
- Full Text
- View/download PDF
36. Évaluation de la relation consommation de fluoroquinolones et émergence de résistance chez Escherichia coli : rôles respectif et comparatif des études observationnelles et quasi expérimentales
- Author
-
Albert Sotto, Jean-Pierre Daurès, and Aba Mahamat
- Subjects
Genetics ,Infectious Diseases ,Quasi experimental study ,Dose effect ,Drug resistance ,Biology ,Antibacterial agent - Abstract
The emergence of Escherichia coli (E. coli) resistance to fluoroquinolones (FQs) increased and spread gradually worldwide since the early 1990s. The selective pressure of FQs is the main mechanism responsible for the emergence of FQ resistance as shown by in vitro studies. Clinical trials are required to prove the causality between exposure to FQs and emergence of resistance. But this would not be ethical in humans. Non experimental studies must answer several principles to establish causality: association, anteriority, and directional change. We described and compared the contribution of observational and quasi-experimental studies implemented to answer several of these principles. Quasi-experimental studies using interventional models (ARIMA models with transfer function), can answer several of these principles, unlike observational studies. Thus, in addition to assessment of the association, they were able to show that the exposure to FQs precedes the emergence of FQ resistance to E. coli. They were also able to estimate the time necessary for the emergence of resistance and the dose effect, and to show if this association was reversible.
- Published
- 2005
- Full Text
- View/download PDF
37. Evolution of fluoroquinolone resistance among Escherichia coli urinary tract isolates from a French university hospital: application of the dynamic regression model
- Author
-
Jean-Pierre Daurès, J.-P. Lavigne, Albert Sotto, Pascale Fabbro-Peray, Aba Mahamat, and Jean-Marie Kinowski
- Subjects
Microbiology (medical) ,fluoroquinolone resistance ,Ofloxacin ,Veterinary medicine ,Time Factors ,Nalidixic acid ,Drug resistance ,Microbiology ,Hospitals, University ,resistance evolution ,Antibiotic resistance ,Anti-Infective Agents ,Ciprofloxacin ,Drug Resistance, Bacterial ,Escherichia coli ,medicine ,Humans ,dynamic regression model ,Escherichia coli Infections ,Norfloxacin ,Antibacterial agent ,business.industry ,General Medicine ,biochemical phenomena, metabolism, and nutrition ,bacterial infections and mycoses ,Defined daily dose ,Infectious Diseases ,Urinary Tract Infections ,Antibiotic use ,Regression Analysis ,France ,business ,Fluoroquinolones ,Forecasting ,medicine.drug - Abstract
Escherichia coli urinary tract isolates were collected in 1997–2003 from NîmesUniversity Hospital in order to investigate long-term trends in antibiotic resistance and to explore the relationship between antibiotic use and the emergence of resistance. Time-series analysis (ARIMA models) and dynamic regression models were used to investigate relationships between antibiotic use and resistance to ofloxacin and ciprofloxacin. Significant increases were seen in the frequency of ofloxacin (8.9 to 16.7%) and ciprofloxacin resistance (6.2 to 10.1%) (p < 0.001). Using multivariate dynamic regression analysis, it was found that an increased use of one defined daily dose (DDD)/1000 patient-days for ofloxacin, ciprofloxacin and norfloxacin induced average increases of 0.81%, 0.65%and 0.53%in E. coli ofloxacin resistance (p < 0.01), with average delays of 4, 4 and 6 months, respectively. An increase of 1 DDD/1000 patient-days of ciprofloxacin, ofloxacin and norfloxacin use induced increases of 0.73%, 0.82% and 0.63% in E. coli ciprofloxacin resistance (p < 0.01), with average delays of 4, 4 and 5 months, respectively. The use of nalidixic acid was not associated significantly with an increase in resistance to fluoroquinolones by multivariate analysis.
- Published
- 2005
- Full Text
- View/download PDF
38. Unique Clone of Coxiella burnetii Causing Severe Q Fever, French Guiana
- Author
-
Philippe Abboud, Félix Djossou, Sophie Edouard, Didier Raoult, Magalie Demar, Aba Mahamat, Bernard La Scola, Antoine Okandze, and Jean-Yves Patrice
- Subjects
Microbiology (medical) ,Cayenne ,Male ,Epidemiology ,Clone (cell biology) ,Virulence ,lcsh:Medicine ,Q fever ,Microbiology ,lcsh:Infectious and parasitic diseases ,medicine ,Endocarditis ,Humans ,lcsh:RC109-216 ,bacteria ,Genotyping ,Phylogeny ,multispacer sequence typing ,clone ,biology ,lcsh:R ,Dispatch ,Endocarditis, Bacterial ,Middle Aged ,Coxiella burnetii ,biology.organism_classification ,medicine.disease ,bacterial infections and mycoses ,Virology ,French Guiana ,Infectious Diseases ,genotyping ,Genes, Bacterial ,Multilocus sequence typing ,Female ,Q Fever ,Pneumonia (non-human) ,Multilocus Sequence Typing - Abstract
Acute Q fever is an emergent and severe disease in French Guiana. We obtained 5 Coxiella burnetii isolates from samples of patients from Cayenne and found an epidemic clone circulating in Cayenne. This clone has caused pneumonia and endocarditis and seems to be more virulent than previously described strains.
- Published
- 2013
39. Molecular Epidemiology of Enterobacteriaceae Isolates Producing Extended-Spectrum β-Lactamases in a French Hospital
- Author
-
N. Bouziges, Aba Mahamat, Albert Sotto, Jean-Philippe Lavigne, Sylvie Michaux-Charachon, and Catherine Chanal
- Subjects
Microbiology (medical) ,Gel electrophoresis ,Inpatients ,Molecular Epidemiology ,biology ,Molecular epidemiology ,Klebsiella pneumoniae ,Enterobacteriaceae Infections ,Bacteriology ,Citrobacter koseri ,biology.organism_classification ,Enterobacter aerogenes ,Enterobacteriaceae ,beta-Lactamases ,Microbiology ,Genotype ,Humans ,France ,Phylogeny ,Bacteria - Abstract
In 2002, 80 isolates of Enterobacteriaceae producing extended-spectrum β-lactamases (ESBLs) were collected from infected patients in our hospital. Enterobacter aerogenes was the most common bacterium isolated from all specimens (36.5%). The ESBLs were predominantly (90%) TEM derivatives (TEM-24, TEM-3). Pulsed-field gel electrophoresis highlighted that E. aerogenes , Klebsiella pneumoniae , and Citrobacter koseri had a clonal propagation.
- Published
- 2004
- Full Text
- View/download PDF
40. Risk factors for multidrug-resistant Pseudomonas aeruginosa nosocomial infection
- Author
-
C. Defez, Pascale Fabbro-Peray, Albert Sotto, Jean-Pierre Daurès, N. Bouziges, A. Gouby, and Aba Mahamat
- Subjects
Male ,medicine.medical_treatment ,Antibiotics ,Comorbidity ,Drug resistance ,medicine.disease_cause ,Severity of Illness Index ,Hospitals, University ,Risk Factors ,Drug Resistance, Multiple, Bacterial ,Surveys and Questionnaires ,Infection control ,Intestinal Mucosa ,Intubation, Gastrointestinal ,Aged, 80 and over ,Cross Infection ,General Medicine ,Middle Aged ,Anti-Bacterial Agents ,Infectious Diseases ,Pseudomonas aeruginosa ,Female ,France ,Urinary Catheterization ,Fluoroquinolones ,Adult ,DNA, Bacterial ,Microbiology (medical) ,medicine.medical_specialty ,Lactams ,medicine.drug_class ,Urinary catheterization ,Microbiology ,Age Distribution ,Enteral Nutrition ,Internal medicine ,Severity of illness ,medicine ,Humans ,Pseudomonas Infections ,Risk factor ,Aged ,Infection Control ,business.industry ,Case-control study ,Logistic Models ,Case-Control Studies ,Multivariate Analysis ,business - Abstract
A case-control study was conducted in a university hospital to determine the risk factors for nosocomial infection with multidrug-resistant Pseudomonas aeruginosa (MDR-PA) among all hospitalized patients and among those with a nosocomial infection due to P. aeruginosa. Eighty patients infected with MDR-PA, 75 infected with a non-MDR phenotype and 240 random controls were included in the 12-month study. Among all hospitalized patients, age, severity index, having a bedridden condition, transfer from other units, nasogastric feeding, urinary catheterization and exposure to beta-lactams (OR=2.5) or fluoroquinolones (OR=4.1) in the seven days before infection were linked to nosocomial infection due to MDR-PA. Among patients infected by P. aeruginosa, exposure to fluoroquinolones (OR=4.7) or surgery (OR=0.5) were linked to the isolation of MDR-PA. This study showed that, in addition to urinary catheterization, nasogastric feeding is an important risk factor in MDR-PA infection. Indeed, an imbalance in gut flora, modifications to the mucous membranes due to the use of nasogastric feeding and the selection pressures exerted by antibiotics were implicated in the occurrence of this infection.
- Published
- 2004
- Full Text
- View/download PDF
41. Effets hémodynamiques du sérum salé hypertonique au cours du choc septique et du sepsis sévère
- Author
-
Laurent Muller, J. Ripart, Guillaume Louart, J.J. Eledjam, J.-E. de La Coussaye, Samir Jaber, Aba Mahamat, and Jean Yves Lefrant
- Subjects
Gynecology ,medicine.medical_specialty ,Anesthesiology and Pain Medicine ,Septic shock ,business.industry ,medicine ,Sepsis syndrome ,Volume loading ,General Medicine ,medicine.disease ,business ,Severe sepsis ,Hypertonic saline - Abstract
Resume Objectif. – Evaluer les effets hemodynamiques de 250 ml de serum sale hypertonique (SSH) a 7,5 % chez des patients de reanimation en sepsis severe ou choc septique. Type d'etude. – Descriptive. Patients. – Douze patients ventiles en choc septique ou sepsis severe monitores par catheter arteriel pulmonaire necessitant une epreuve de remplissage. Methodes. – Deux cent cinquante millilitres de SSH ont ete administres en 15 minutes. Parametres etudies : frequence cardiaque (FC), pression arterielle moyenne (PAM), pression moyenne de l'artere pulmonaire (PAPm), pression de l'oreillette droite (POD), index cardiaque (IC), resistances vasculaires systemiques et pulmonaires indexees (RVSI, RVPI), natremie, chloremie, protidemie, hemoglobine, lactates arteriels. Ces parametres sont mesures avant traitement (Temps 0 = T0), a 5 (T20) et 105 (T120) minutes apres la fin de la perfusion. Resultats. – La PAM, la FC et la POD etaient inchangees. Le SSH a augmente la PAPm (25 ± 5 to 30 ± 6mmHg), la PAPO (13 ± 3 to 18 ± 4 mmHg) et l'IC (3,5 ± 1,2 to 4,6 ± 1,1 l/minute par m2) a T20 (p Conclusion. – Chez des patients en sepsis severe ou en choc septique, l'administration de 250 ml de SSH 7,5 % induit une augmentation transitoire (2 heures) de l'IC et de la PAPO associee a une hemodilution et une elevation de la natremie et de la chloremie.
- Published
- 2004
- Full Text
- View/download PDF
42. Ophthalmic Regional Anesthesia
- Author
-
Jacques Ripart, Pierre Charavel, B. Bassoul, Joël L’Hermite, Philippe Mahiou, Martine Mainemer, Jean-Jacques Eledjam, Arnaud Chaumeron, Emmanuel Nouvellon, Stéphane Dareau, Gerard Dupeyron, and Aba Mahamat
- Subjects
medicine.medical_specialty ,Anesthesiology and Pain Medicine ,business.industry ,Regional anesthesia ,Mortise and tenon ,Medicine ,Canthus ,Single injection ,business ,Prospective cohort study ,Surgery - Abstract
Background The purpose of this study was to evaluate the efficacy and safety of episcleral single-injection anesthesia in a large number of patients. Methods Over a period of 5 yr, in four institutions, anesthesiologists involved in this prospective study completed a standardized form to evaluate single-injection medial canthus high-volume episcleral anesthesia. The success rate of the block was rated according to an akinesia score. The study parameters included demographic data, surgical procedure, and anesthetic management. All patients were followed up at least until postoperative day 1, and all complications, pain, and discomfort were noted. Statistical analysis was done to assess the risk factors for complications. Results A total of 2,031 patients were included in the study. The most frequent surgical procedures performed were phacoemulsification and posterior chamber artificial lens implantation (91.0%). A total of 66 complications (3.3%) occurred in 60 patients. One patient had a retrobulbar hemorrhage, and 59 had one or two more minor incidents or pain/discomfort with the procedure. The complications consisted of subconjunctival hematoma (1.3%), ocular hypertonia (0.4%), and chemosis (0.30%). Statistical analysis revealed that inexperience in the technique represented a risk factor for complications. Conclusions This is the first survey of a large experience in episcleral single-injection anesthesia, a form of anesthesia that does not preclude sharp-needle complications and does require training. Only one complication occurred among 2,031 patients; however, a larger number of patients is needed to definitively evaluate the safety of episcleral single-injection anesthesia.
- Published
- 2004
- Full Text
- View/download PDF
43. Body mass index, hypertension and 5-year coronary heart disease incidence in middle aged men
- Author
-
Aba Mahamat, Florence Richard, Dominique Arveiler, Vanina Bongard, John Yarnell, Pierre Ducimetière, Jean-Bernard Ruidavets, Bernadette Haas, Annie Bingham, Alun Evans, Philippe Amouyel, and Jean Dallongeville
- Subjects
Male ,Physiology ,Coronary Disease ,Middle Aged ,Body Mass Index ,Risk Factors ,Hypertension ,Internal Medicine ,Humans ,France ,Obesity ,Prospective Studies ,Cardiology and Cardiovascular Medicine ,Ireland - Abstract
The aim of the present study was to assess the joint contribution of hypertension and body mass index to coronary heart disease risk. DESIGN Prospective study on men aged 50-59 years free of coronary heart disease at entry recruited in three regions of France (n = 7359) and in Northern Ireland (n = 2399).The recruitment frame was based on industry and various employment groups, on health screening centers and general practice.Incident cases of effort angina, unstable angina, myocardial infarction and coronary death were recorded over a 5-year follow-up.Compared with the reference group [body mass index (BMI) 25 kg/m2], the relative risk of coronary event was higher in the second (25or =BMI 27.6) and third BMI tertiles: 1.27 (95% confidence interval 0.94-1.70) and 1.14 (0.84-1.56) after adjustment for confounders and covariates, including diabetes, hypertension and lipoprotein levels. Further analyses revealed a significant interaction between hypertension and BMI on coronary disease risk (P0.05), suggesting that hypertension modifies coronary heart disease (CHD) risk attributable to BMI. Among hypertensive men, the relative risk of coronary heart disease was 1.34 (0.85-2.11) and 1.61 (1.04-2.50) in the second and third BMI tertiles, respectively. In normotensive men, BMI was not associated with CHD risk; relative risk 1.25 (0.85-1.85) and 0.66 (0.40-1.09) in the second and third BMI, respectively.These results indicate that hypertension and overweight jointly increase coronary heart disease risk.
- Published
- 2003
- Full Text
- View/download PDF
44. Pneumocystis jiroveci Pneumonia Revealing De Novo Mutation Causing X-Linked Hyper-IgM Syndrome in an Infant Male. The First Case Reported From French Guiana
- Author
-
Geneviève de Saint Basile, Narcisse Elenga, Frederique Dulorme, and Aba Mahamat
- Subjects
Male ,Pneumocystis jiroveci pneumonia ,Pediatrics ,medicine.medical_specialty ,X-Linked Hyper IgM Syndrome ,business.industry ,Pneumonia, Pneumocystis ,Genetic counseling ,Infant ,De novo mutation ,Genetic Diseases, X-Linked ,Hematology ,Hyper-IgM Immunodeficiency Syndrome ,Pneumocystis carinii ,medicine.disease ,Hypogammaglobulinemia ,Pneumonia ,Oncology ,Mutation ,Pediatrics, Perinatology and Child Health ,medicine ,Primary immunodeficiency ,Humans ,Pediatric unit ,business - Abstract
BACKGROUND The X-linked hyper-IgM (XHIM) syndrome is a rare form of primary immunodeficiency disorder characterized by hypogammaglobulinemia and impaired cell immunity. OBSERVATION We report history of Guianese family affected by XHIM syndrome. The eldest boy died at 7 months from pneumonia. The 5-month-old youngest boy presented with a potentially fatal episode of Pneumocystis jiroveci pneumonia. The diagnosis was done in the Pediatric Unit of Immunohematology of Hopital Necker in Paris. CONCLUSIONS This report points to the importance of diagnosis of XHIM to allow early treatment to minimize serious infections and to detect carriers in XHIM families for genetic counseling.
- Published
- 2012
- Full Text
- View/download PDF
45. Critical Importance of Long-Term Adherence to Care in HIV Infected Patients in the cART Era: New Insights from Pneumocystis jirovecii Pneumonia Cases over 2004–2011 in the FHDH-ANRS CO4 Cohort
- Author
-
Frédéric Méchaï, Dominique Costagliola, Nathalie De Castro, Blandine Denis, Giovanna Melica Gregoire, Matthieu Revest, Olivier Lortholary, Marguerite Guiguet, Aba Mahamat, Institut Pierre Louis d'Epidémiologie et de Santé Publique ( iPLESP ), Institut National de la Santé et de la Recherche Médicale ( INSERM ) -Université Pierre et Marie Curie - Paris 6 ( UPMC ), Université Paris Diderot - Paris 7 ( UPD7 ), Service des maladies infectieuses [CHU St Louis], Groupe Hospitalier Saint Louis - Lariboisière - Fernand Widal [Paris], Service de maladies infectieuses et tropicales [CHU Avicenne], Hôpital Avicenne, Services de maladies infectieuses et tropicales [CHU Rennes], CHU Pontchaillou [Rennes], Unité des Maladies Infectieuses et Tropicale, Centre Hospitalier de Cayenne, Centre Hospitalier Andrée Rosemon [Cayenne, Guyane Française], Groupe de Recherche en Informatique et Mathématiques Appliquées Antilles-Guyane ( GRIMAAG ), Université des Antilles et de la Guyane ( UAG ), Centre d'infectiologie Necker-Pasteur [CHU Necker], Assistance publique - Hôpitaux de Paris (AP-HP)-CHU Necker - Enfants Malades [AP-HP], Imagine - Institut des maladies génétiques ( IMAGINE - U1163 ), Université Paris Descartes - Paris 5 ( UPD5 ) -Institut National de la Santé et de la Recherche Médicale ( INSERM ) -Centre National de la Recherche Scientifique ( CNRS ), Centre National de Référence des Mycoses invasives et antifongiques - Mycologie moléculaire ( CNRMA ), Institut Pasteur [Paris]-Centre National de la Recherche Scientifique ( CNRS ), Institut Pierre Louis d'Epidémiologie et de Santé Publique (iPLESP), Université Pierre et Marie Curie - Paris 6 (UPMC)-Institut National de la Santé et de la Recherche Médicale (INSERM), Université Paris Diderot - Paris 7 (UPD7), Assistance publique - Hôpitaux de Paris (AP-HP) (AP-HP)-Assistance publique - Hôpitaux de Paris (AP-HP) (AP-HP), Hôpital Avicenne [AP-HP], Service des maladies infectieuses et réanimation médicale [Rennes] = Infectious Disease and Intensive Care [Rennes], Groupe de Recherche en Informatique et Mathématiques Appliquées Antilles-Guyane (GRIMAAG), Université des Antilles et de la Guyane (UAG), CHU Necker - Enfants Malades [AP-HP], Assistance publique - Hôpitaux de Paris (AP-HP) (AP-HP)-Assistance publique - Hôpitaux de Paris (AP-HP) (AP-HP)-Institut Pasteur [Paris], Imagine - Institut des maladies génétiques (IMAGINE - U1163), Université Paris Descartes - Paris 5 (UPD5)-Institut National de la Santé et de la Recherche Médicale (INSERM), Centre National de Référence des Mycoses invasives et antifongiques - Mycologie moléculaire (CNRMA), Institut Pasteur [Paris]-Centre National de la Recherche Scientifique (CNRS), Institut Pasteur [Paris] (IP)-CHU Necker - Enfants Malades [AP-HP], Institut Pasteur [Paris] (IP)-Centre National de la Recherche Scientifique (CNRS), Institut National de la Santé et de la Recherche Médicale (INSERM)-Université Pierre et Marie Curie - Paris 6 (UPMC), Service des maladies infectieuses et réanimation médicale [Rennes], Université de Rennes 1 (UR1), Université de Rennes (UNIV-RENNES)-Université de Rennes (UNIV-RENNES)-Hôpital Pontchaillou, Institut Pasteur [Paris]-CHU Necker - Enfants Malades [AP-HP], Assistance publique - Hôpitaux de Paris (AP-HP) (APHP)-Assistance publique - Hôpitaux de Paris (AP-HP) (APHP), and Centre National de la Recherche Scientifique (CNRS)-Université Paris Descartes - Paris 5 (UPD5)-Institut National de la Santé et de la Recherche Médicale (INSERM)
- Subjects
medicine.medical_specialty ,Viral Diseases ,Epidemiology ,lcsh:Medicine ,Context (language use) ,HIV Infections ,Kaplan-Meier Estimate ,Pneumocystis carinii ,Microbiology ,Men who have sex with men ,Immunodeficiency Viruses ,[SDV.MHEP.MI]Life Sciences [q-bio]/Human health and pathology/Infectious diseases ,Internal medicine ,medicine ,Pneumocystis jirovecii ,Humans ,Intensive care medicine ,lcsh:Science ,Microbial Pathogens ,Medicine and health sciences ,Multidisciplinary ,biology ,Population Biology ,business.industry ,Proportional hazards model ,Pneumocystis ,Incidence (epidemiology) ,Mortality rate ,Clinical epidemiology ,lcsh:R ,Fungal Diseases ,Biology and Life Sciences ,HIV ,Pneumonia ,biology.organism_classification ,3. Good health ,[ SDV.MHEP.MI ] Life Sciences [q-bio]/Human health and pathology/Infectious diseases ,Infectious Diseases ,Medical Microbiology ,HIV epidemiology ,Viral Pathogens ,Cohort ,CD4 Antigens ,Patient Compliance ,lcsh:Q ,business ,Viral load ,Research Article ,Infectious disease epidemiology - Abstract
International audience; Objective: To describe characteristics and outcomes of HIV-infected patients with Pneumocystis jirovecii pneumonia (PCP) over 2004–2011 in France, in particular in those previously enrolled (PE) in the French Hospital Database on HIV (FHDH). Methods: PE patients with an incident PCP were compared with patients with an inaugural PCP revealing HIV infection (reference). Adequate adherence to care was defined as a CD4 measurement at least every 6 months. Immune reconstitution (CD4$200/mm 3) and risk of death were studied using Kaplan-Meier estimates and multivariable Cox proportional hazards models. Results: In a context of a decreasing incidence of PCP, 1259 HIV-infected patients had a PCP diagnosis, and 593 (47%) were PE patients of whom 161 (27%) have had a prior history of AIDS-defining clinical illness (prior ADI). Median time since enrolment was 8 years for PE patients; 74% had received cART. Median proportion of time with adequate adherence to care was 85% (IQR, 66–96) for all FHDH enrollees, but only 45% (IQR, 1–81) for PE patients during the 2 years before PCP. Median CD4 cell count (38/mm 3) and HIV viral load (5.2 log10 copies/ml) at PCP diagnosis did not differ between PE patients and the reference group. Three year mortality rate of 25% was observed for PE prior ADI group, higher than in PE non-prior ADI group (8%) and the reference group (9%) (p,0.0001). In the PE prior ADI group, poor prognosis remained even after adjustment for virological control and immune reconstitution (HR, 2.4 [95%CI, 1.5–3.7]). Conclusion: Almost 50% of PCP diagnoses in HIV-infected patients occurred presently in patients already in care, mainly with a previous cART prescription but with waning adherence to care. Having repeated ADI is contributing to the risk of death beyond its impact on immune reconstitution and viral suppression: special efforts must be undertaken to maintain those patients in care.
- Published
- 2014
- Full Text
- View/download PDF
46. Response to Alonso et al
- Author
-
C. Viboud and Aba Mahamat
- Subjects
Microbiology (medical) ,Infectious Diseases ,Geography ,Climate ,Influenza, Human ,Humans ,Humanities - Published
- 2014
47. High Prevalence of HBsAg during Pregnancy in Asian Communities at Cayenne Hospital, French Guiana
- Author
-
Dominique Louvel, Aba Mahamat, Tania Vaz, Mathieu Nacher, Félix Djossou, and Magalie Demar
- Subjects
HBsAg ,medicine.medical_specialty ,Prevalence ,Ethnic group ,medicine.disease_cause ,Pregnancy ,Virology ,Epidemiology ,medicine ,Humans ,Hepatitis B virus ,Hepatitis B Surface Antigens ,business.industry ,virus diseases ,Articles ,Hepatitis B ,medicine.disease ,digestive system diseases ,French Guiana ,Infectious Diseases ,Tropical medicine ,Immunology ,Female ,Parasitology ,business ,Demography - Abstract
We described hepatitis B surface antigen (HBsAg) prevalence among 2,347 pregnant women having delivered at the Cayenne hospital in 2007 according to ethnicity. With 11.0% HBsAg prevalence, Asian women (Hmong and Chinese) were the group with the highest risk of hepatitis B virus (HBV) perinatal transmission compared with other ethnic groups.
- Published
- 2010
- Full Text
- View/download PDF
48. Increased incidence of mucosal candidiasis after HAART initiation: a benign form of immune reconstitution disease?
- Author
-
Christine Aznar, Mathieu Nacher, Vincent Vantilcke, Florence Huber, Myriam El Guedj, Bernard Carme, Aba Mahamat, Andry Randrianjohany, E. Clyti, and Pierre Couppié
- Subjects
Male ,medicine.medical_specialty ,Opportunistic infection ,medicine.medical_treatment ,AIDS-Related Opportunistic Infections ,Immunology ,HIV Infections ,Immune system ,Immune reconstitution inflammatory syndrome ,Immune Reconstitution Inflammatory Syndrome ,Antiretroviral Therapy, Highly Active ,parasitic diseases ,Epidemiology ,medicine ,Humans ,Immunology and Allergy ,Mycosis ,Retrospective Studies ,Chemotherapy ,business.industry ,Incidence ,Incidence (epidemiology) ,Candidiasis ,Middle Aged ,medicine.disease ,French Guiana ,Infectious Diseases ,HIV-1 ,Female ,business - Abstract
Immune reconstitution after HAART initiation is often complicated by adverse clinical manifestations caused either by the unmasking of preexisting untreated opportunistic infections or the clinical deterioration of a known and treated opportunistic infection. The present study was conducted to determine whether the initiation of HAART was followed by an increase in the incidence of mucosal candidiases, a possible manifestation of immune reconstitution disease of the unmasking type.
- Published
- 2007
- Full Text
- View/download PDF
49. Combined antiparasitic treatment for neurocysticercosis
- Author
-
P. Abboud, Magalie Demar, F. Djossou, Aba Mahamat, and Daniel JeanBourquin
- Subjects
medicine.medical_specialty ,medicine.diagnostic_test ,business.industry ,Antiparasitic Drugs ,Neurocysticercosis ,Cysticercosis ,Computed tomography ,medicine.disease ,Albendazole ,Malaise ,Praziquantel ,Infectious Diseases ,parasitic diseases ,medicine ,Cyst ,Radiology ,medicine.symptom ,business ,medicine.drug - Abstract
264 www.thelancet.com/infection Vol 15 March 2015 of cystic viable lesions on the MRI from Oct 23, 2011. Furthermore, the patient presented symptomatic subcutaneous and intramuscular cysts with scolex shown by high-resolution sonography. Thus, we gave him a repeated course of standard doses of albendazole on Dec 20, 2011. On Aug 22, 2012, he had malaise, and we did a MRI showing persistence of viable cysts. He was fi nally successfully treated with a combination of albendazole and praziquantel at standard doses on Nov 11, 2012. Further neuroimaging surveillance showed residual calci fications on a CT scan and no viable cyst on MRI on Sept 14, 2013. We strongly recommend bitherapy of antiparasitic drugs for treatment of multicystic parenchymal neuro cysticercosis.
- Published
- 2015
- Full Text
- View/download PDF
50. Climatic Drivers Of Seasonal Influenza Epidemics In French Guiana, 2006–2010
- Author
-
A. Bouix, Luisiane Carvalho, F. Eltges, M.A. Miller, C. Viboud, Philippe Quénel, Philippe Dussart, Séverine Matheus, Aba Mahamat, National Institutes of Health [Bethesda] (NIH), Centre Hospitalier Andrée Rosemon [Cayenne, Guyane Française], Université des Antilles et de la Guyane (UAG), Institut Pasteur de la Guyane, Réseau International des Instituts Pasteur (RIIP), GP Sentinel Network on Influenza Surveillance [Cayenne, Guyane française], Cellule de l'Institut de Veille Sanitaire en régions Antilles Guyane, Agence Régionale de la Santé [Cayenne, Guyane française] (ARS), This research was conducted in the context of the Multinational Influenza Seasonal Mortality Study (MISMS), an on-going international collaborative effort to understand influenza epidemiological and evolutionary patterns, led by the Fogarty International Center, National Institutes of Health. Funding for this project comes from the Office of Global Affairs' International Influenza Unit in the Office of the Secretary of the Department of Health and Human Services. This work has benefited from an 'Investissement d'Avenir' grant managed by Agence Nationale de la Recherche (CEBA, ref. ANR-10-LABX-0025)., and ANR-10-LABX-0025,CEBA,CEnter of the study of Biodiversity in Amazonia(2010)
- Subjects
Microbiology (medical) ,Wet season ,Rainfall ,Veterinary medicine ,Climate ,Orthomyxoviridae ,Influenza epidemics ,Biology ,ARIMA ,Article ,Seasonal influenza ,03 medical and health sciences ,0302 clinical medicine ,Tropical ,MESH: French Guiana ,MESH: Humidity ,medicine ,Times-series ,030212 general & internal medicine ,MESH: Incidence ,030304 developmental biology ,MESH: Orthomyxoviridae ,0303 health sciences ,MESH: Humans ,Incidence (epidemiology) ,MESH: Influenza, Human ,virus diseases ,Humidity ,Dynamic regression ,Influenza transmission ,Seasonality ,medicine.disease ,biology.organism_classification ,MESH: Climate ,Influenza ,MESH: Nasopharynx ,Infectious Diseases ,[SDV.MP.VIR]Life Sciences [q-bio]/Microbiology and Parasitology/Virology ,MESH: Rain ,[SDV.SPEE]Life Sciences [q-bio]/Santé publique et épidémiologie ,MESH: Seasons - Abstract
International audience; ObjectivesInfluenza seasonality remains poorly studied in Equatorial regions. Here we assessed the seasonal characteristics and environmental drivers of influenza epidemics in French Guiana, where influenza surveillance was established in 2006.MethodsSentinel GPs monitored weekly incidence of Influenza-like illnesses (ILI) from January 2006 through December 2010 and collected nasopharyngeal specimens from patients for virological confirmation. Times series analysis was used to investigate relationship between ILI and climatic parameters (rainfall and specific humidity).ResultsBased on 1533 viruses identified during the study period, we observed marked seasonality in the circulation of influenza virus in the pre-pandemic period, followed by year-round activity in the post-pandemic period, with a peak in the rainy season. ILI incidence showed seasonal autoregressive variation based on ARIMA analysis. Multivariate dynamic regression revealed that a 1 mm increase of rainfall resulted in an increase of 0.33% in ILI incidence one week later, adjusting for specific humidity (SH). Conversely, an increase of 1 g/kg of SH resulted in a decrease of 11% in ILI incidence 3 weeks later, adjusting for rainfall.ConclusionsIncreased rainfall and low levels of specific humidity favour influenza transmission in French Guiana.
- Published
- 2013
- Full Text
- View/download PDF
Catalog
Discovery Service for Jio Institute Digital Library
For full access to our library's resources, please sign in.